Tamas Hickish

Tamas Hickish

  • thickish at bournemouth dot ac dot uk
Back to top

Biography

Consultant Medical Oncologist, Dorset Cancer Centre c/o Royal Bournemouth Hospital Visiting Professor Bournemouth University Medical Director iQHealth Tech

Research

Point of Care testing using pin prick blood testing for neutrophil count in patients receiving chemotherapy.

Exploring AI/Machine learning to interogate ECHO data in patients receiving Trastuzumab.

Journal Articles

  • Iveson, T., Saunders, M.P., Kelly, C., Kerr, R.S., Cassidy, J., Hollander, N.H., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Pearson, S., Boyd, K.A., Briggs, A.H., Waterston, A., Medley, L., Ellis, R., Dhadda, A.S., Harrison, M., Falk, S., Rees, C., Olesen, R.K., Propper, D., Bridgewater, J., Azzabi, A., Cunningham, D., Hickish, T., Gollins, S., Wasan, H.S., Church, D., Domingo, E., 2026. Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial. J Clin Oncol, JCO2500621.
  • Gögenur, M., Weinberger Rosen, A., Iveson, T., Kerr, R.S., Saunders, M.P., Cassidy, J., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., Pearson, S., Boyd, K.A., Briggs, A.H., Waterston, A., Medley, L., Ellis, R., Dhadda, A.S., Harrison, M., Falk, S., Rees, C., Olesen, R.K., Propper, D., Bridgewater, J., Azzabi, A., Cunningham, D., Hickish, T., Gollins, S., Wasan, H.S., Kelly, C., Gögenur, I., Holländer, N.H., 2024. Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy Post Hoc Analysis of the SCOT Randomized Clinical Trial. JAMA Surgery, 159 (8), 865-871.
  • Glasbey, J., Beggs, A., Glimelius, B., Gray, R., Laurberg, S., Magill, L., Murakami, K., Palmer, A., Quirke, P., Seligman, J., Seymour, M., Sinha, Y., West, N., Morton, D., Crosby, T., Olliff, J., Peto, R., Brown, G., Ferry, D., Ismail, T., Oliver, A., Quirke, P., Scott, N., Swift, I., Warren, B., Northover, J., Parmar, M., Slevin, M., Wilcockson, A., Gray, Z., Lancaster, D., Brown, J., Palmer, A., Adie, L., Kennedy, G., Eld, M., Holt, G., Yilmaz, M., Spendler, K.G., Hansen, F., Laurberg, S., Rosenkilde, M., Ahlstrom, H., Glimelius, B., Abgamu, D., Day, N., Walsh, C., Bannister, J., Furniss, D., Morgan, S., Walkington, L., Yates, S., Branagan, G., Mustajab, A., O’Neil, H., Rees, C., Geh, I., Hendrickse, C., Langman, G., Pallan, A., Conn, A., Lowe, A., Ostrowski, J., Steward, M., Callaway, M., Falk, S., Thomas, M., Wong, N., Cast, J., Hartley, J., Roy, R., Tiam, R., Blunt, D., Cleator, S., Dawson, P., Goldin, R., Gujral, D., Lowdell, C., Ziprin, P., Clenton, S., Dewdney, A., Euinton, H., Gupta, R., Tarapowewalla, D., Wilshaw, V., Braun, M., Chakrabarty, B., Laasch, H., Saunders, M., Cruickshank, N., Davies, M., Muzaffar, S., Orme, A., Punia, P., Rea, D., Hughes, M., Palmer, D., Rooney, P., 2024. Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer: A Nested Case-control-matched Analysis of an International, Multicenter, Randomized Controlled Trial (FOxTROT). Annals of Surgery, 280 (2), 283-293.
  • Abraham, J.E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L.M., Lucey, R., Fulton, A., Roberts, A.N., Worley, J.R., Chhabra, A., Qian, W., Vallier, A.L., Hardy, R.M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J.P., Sutherland, S., Staples, E., Scott, L.C., Davies, M., Palmer, C.A., Moody, M., Churn, M.J., Newby, J.C., Mukesh, M.B., Chakrabarti, A., Roylance, R.R., Schouten, P.C., Levitt, N.C., McAdam, K., Armstrong, A.C., Copson, E.R., McMurtry, E., Tischkowitz, M., Provenzano, E., Earl, H.M., 2024. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature, 629 (8014), 1142-1148.
  • Holt, S., Verrill, M., Pettit, L., Rigg, A., Hickish, T., Archer, C., Dent, J., Dillon, M., Nathan, M., Barthelmes, L., Rehman, S., Sharaiha, Y., Innis, P., Sai-Giridhar, P., Khawaja, S., 2024. A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer. British Journal of Cancer, 130 (7), 1149-1156.
  • Coakley, M., Villacampa, G., Sritharan, P., Swift, C., Dunne, K., Kilburn, L., Goddard, K., Pipinikas, C., Rojas, P., Emmett, W., Hall, P., Harper-Wynne, C., Hickish, T., Macpherson, I., Okines, A., Wardley, A., Wheatley, D., Waters, S., Palmieri, C., Winter, M., Cutts, R.J., Garcia-Murillas, I., Bliss, J., Turner, N.C., 2024. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 30 (4), 895-903.
  • Turner, N.C., Swift, C., Jenkins, B., Kilburn, L., Coakley, M., Beaney, M., Fox, L., Goddard, K., Garcia-Murillas, I., Proszek, P., Hall, P., Harper-Wynne, C., Hickish, T., Kernaghan, S., Macpherson, I.R., Okines, A.F.C., Palmieri, C., Perry, S., Randle, K., Snowdon, C., Stobart, H., Wardley, A.M., Wheatley, D., Waters, S., Winter, M.C., Hubank, M., Allen, S.D., Bliss, J.M., S. Chan, Armstrong, A., Raja, F., Schmid, P., Tutt, A., Roux, R., Cleator, S., 2023. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Annals of Oncology, 34 (2), 200-211.
  • Ring, A., Kilburn, L.S., Pearson, A., Moretti, L., Afshari-Mehr, A., Wardley, A.M., Gurel, B., Macpherson, I.R., Riisnaes, R., Baird, R.D., Martin, S., Roylance, R., Johnson, H., Ferreira, A., Winter, M.C., Dunne, K., Copson, E., Hickish, T., Burcombe, R., Randle, K., Serra, V., Llop-Guevara, A., Bliss, J.M., Turner, N.C., 2023. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). Clinical Cancer Research, 29 (23), 4751-4759.
  • Geyer, C.E., Garber, J.E., Gelber, R.D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A.C., Arnedos, M., Balmaña, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S.M., Eisen, A., Elsafy, F., Fein, L.E., Fielding, A., Ford, J.M., Friedman, S., Gelmon, K.A., Gianni, L., Gnant, M., Hollingsworth, S.J., Im, S.A., Jager, A., Jóhannsson, Lakhani, S.R., Janni, W., Linderholm, B., Liu, T.W., Loman, N., Korde, L., Loibl, S., Lucas, P.C., Marmé, F., Martinez de Dueñas, E., McConnell, R., Phillips, K.A., Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C.F., Španić, T., Stickeler, E., Toi, M., Traina, T.A., Viale, G., Zoppoli, G., Park, Y.H., Yerushalmi, R., Yang, H., Pang, D., Jung, K.H., Mailliez, A., Fan, Z., Tennevet, I., Zhang, J., Nagy, T., Sonke, G.S., Sun, Q., Parton, M., Colleoni, M.A., Schmidt, M., Brufsky, A.M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., Tutt, A.N.J., Sevelda, P., Haslbauer, F., Penzinger, M., Öhler, L., Tinchon, C., Greil, R., Heibl, S., Bartsch, R., Wette, V., Pasterk, C., Helfgott, R., Pristauz-Telsnigg, G., Stöger, H., Weltermann, A., Egle, D., Thiel, I., Fuchs, D., Rumpold, H., Strasser-Weippl, K., Rautenberg, B., Müller, V., Schmidt, M., Paepke, S., 2022. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology, 33 (12), 1250-1268.
  • Hickish, T., Mehta, A., Liu, M.C., Huang, C.S., Arora, R.S., Chang, Y.C., Yang, Y., Vladimirov, V., Jain, M., Tsang, J., Pemberton, K., Sadrolhefazi, B., Jin, X., Tseng, L.M., 2022. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast Cancer Research and Treatment, 192 (3), 593-602.
  • Tutt, A.N.J., Garber, J.E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R.D., de Azambuja, E., Fielding, A., Balmaña, J., Domchek, S.M., Gelmon, K.A., Hollingsworth, S.J., Korde, L.A., Linderholm, B., Bandos, H., Senkus, E., Suga, J.M., Shao, Z., Pippas, A.W., Nowecki, Z., Huzarski, T., Ganz, P.A., Lucas, P.C., Baker, N., Loibl, S., McConnell, R., Piccart, M., Schmutzler, R., Steger, G.G., Costantino, J.P., Arahmani, A., Wolmark, N., McFadden, E., Karantza, V., Lakhani, S.R., Yothers, G., Campbell, C., Geyer, C.E., OlympiA Clinical Trial Steering Committee and Investigators, 2021. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med, 384 (25), 2394-2405.
  • Pritchard, C., Birch, B., Hickish, T., Rosenorn-Lanng, E., 2021. Comparing Total Neoplasms, Breast & Prostate Cancer Mortality Rates of the UK and 20 Major Developed Countries 1989-91 v 2013- 15 - Identifying Progress. Archive Internal Medical Research, 4 (1), 19-30.
  • Bridgewater, J.A., Pugh, S.A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., Stanton, L., Radford, M., Corkhill, A., Griffiths, G.O., Falk, S., Valle, J.W., O'Reilly, D., Siriwardena, A.K., Hornbuckle, J., Rees, M., Iveson, T.J., Hickish, T., Garden, O.J., Cunningham, D., Maughan, T.S., Primrose, J.N., Shablack, A., O'Callaghan, A., Moody, A., Allen, A., Brewster, A., Brown, A., Mayer, A., Davidson, B., Ton, C., Wilson, C., Lowdell, C., Rees, C., Baughan, C., Barlow, C., Purcell, C., Smith, D., Tsang, D., Brown, E., Walker, G., Malik, H., Cameron, I., Nolan, L., Hall, M., Tomlinson, M., Hill, M., Peterson, M., Finch-Jones, M., Kumar, N., Karanjia, N., Ali, N., Heaton, N., Ton, N.C., Ross, P., Praseedom, R., Thomas, R., Clive, S., Slater, S., Smith, S., Mudan, S., Bhattacharya, S., Essapen, S., Raouf, S., Fenwick, S., Cleator, S., Diamond, T., Potter, V., 2020. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, 21 (3), 398-411.
  • Mansbridge, C., Simmonds, P., Murray, N., Davies, A., Stanton, L., Chinnery, F., Archer, C., Barrett-Lee, P., Hickish, T., Crabb, S., 2020. A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes. F1000Research, 9.
  • Ivesono, T., Boydo, K.A., Kerro, R.S., Robles-Zuritao, J., Saunders, M.P., Briggso, A.H., Cassidyo, J., Hollandero, N.H., Taberneroo, J., Haydon, A., Glimeliuso, B., Harkino, A., Allano, K., McQueeno, J., Pearsono, S., Waterstono, A., Medleyo, L., Wilsono, C., Elliso, R., Essapen, S., Dhaddao, A.S., Harrison, M., Falko, S., Raoufo, S., Rees, C., Oleseno, R.K., Proppero, D., Bridgewatero, J., Azzabio, A., Farrugiao, D., Webbo, A., Cunninghamo, D., Hickish, T., Weavero, A., Gollins, S., Wasano, H., Paulo, J., 2019. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage ii and iii colorectal cancer: 3-year follow-up of the scot non-inferiority rct. Health Technology Assessment, 23 (64), 1-88.
  • Jones, R.P., Psarelli, E.-E., Jackson, R., Ghaneh, P., Halloran, C.M., Palmer, D.H., Campbell, F., Valle, J.W., Faluyi, O., O'Reilly, D.A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J.R., Middleton, G.W., Cummins, S., Ross, P.J., Wasan, H., McDonald, A., Crosby, T., Ting, Y., Patel, K., Sherriff, D., Soomal, R., Borg, D., Sothi, S., Hammel, P., Lerch, M.M., Mayerle, J., Tjaden, C., Strobel, O., Hackert, T., Büchler, M.W., Neoptolemos, J.P., European Study Group for Pancreatic Cancer, 2019. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg, 154 (11), 1038-1048.
  • Huober, J., Holmes, E., Baselga, J., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Lang, I., Smith, I., Boyle, F., Xu, B., Lecocq, C., Wildiers, H., Jouannaud, C., Hackman, J., Dasappa, L., Ciruelos, E., Toral Pena, J.C., Adamchuk, H., Hickish, T., de la Pena, L., Jackisch, C., Gelber, R.D., Piccart-Gebhart, M., Di Cosimo, S., 2019. Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European Journal of Cancer, 118, 169-177.
  • Auclin, E., André, T., Taieb, J., Banzi, M., Van Laethem, J.L., Tabernero, J., Hickish, T., de Gramont, A., Vernerey, D., 2019. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. British Journal of Cancer, 121 (4), 312-317.
  • Primrose, J.N., Fox, R.P., Palmer, D.H., Malik, H.Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., Wasan, H., Ross, P., Wall, L., Wadsley, J., Evans, J.T.R., Stocken, D., Praseedom, R., Ma, Y.T., Davidson, B., Neoptolemos, J.P., Iveson, T., Raftery, J., Zhu, S., Cunningham, D., Garden, O.J., Stubbs, C., Valle, J.W., Bridgewater, J., Morement, H., Chan, O., Rees, C., Hickish, T., Pope, I., Crosby, T., Sothi, S., Sharkland, K., Adamson, D., Dent, J., Hombaiah, U., Iwuji, C., Anthoney, A., Gillmore, R., Slater, S., Waters, J., Palmer, D., Faluyi, O., Sumpter, K., Dernedde, U., Maduhusudan, S., Cogill, G., Archer, C., Darby, S., Peterson, M., Mukhtar, A.A., Thorpe, J.G., Bateman, A., Tsang, D., Cummins, S., Nolan, L., Beaumont, E., Garden, J., Coxon, F., 2019. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology, 20 (5), 663-673.
  • Kurzrock, R., Hickish, T., Wyrwicz, L., Saunders, M., Wu, Q., Stecher, M., Mohanty, P., Dinarello, C.A., Simard, J., 2019. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology, 8 (3).
  • Auclin, E., Taieb, J., Lepage, C., Aparicio, T., Faroux, R., Mini, E., Folprecht, G., Salazar, R., Benetkiewicz, M., Banzi, M., Louvet, C., Van Laethem, J.L., Tabernero, J., Hickish, T., De Gramont, A., Andre, T., Vernerey, D., 2019. Carcinoembryonic antigen levels and survival in stage III colon cancer: Post hoc analysis of the MOSAIC and PETACC-8 trials. Cancer Epidemiology Biomarkers and Prevention, 28 (7), 1153-1161.
  • Robles-Zurita, J., Boyd, K.A., Briggs, A.H., Iveson, T., Kerr, R.S., Saunders, M.P., Cassidy, J., Hollander, N.H., Tabernero, J., Segelov, E., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Pearson, S., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., Dhadda, A.S., Hughes, R., Falk, S., Raouf, S., Rees, C., Olesen, R.K., Propper, D., Bridgewater, J., Azzabi, A., Farrugia, D., Webb, A., Cunningham, D., Hickish, T., Weaver, A., Gollins, S., Wasan, H.S., Paul, J., 2018. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119 (11), 1332-1338.
  • Cidon, E.U., Martinez, P.A., Hickish, T., 2018. Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literatureN. World Journal of Clinical Cases, 6 (12), 531-537.
  • Jankowski, J.A.Z., de Caestecker, J., Love, S.B., Reilly, G., Watson, P., Sanders, S., Ang, Y., Morris, D., Bhandari, P., Brooks, C., Attwood, S., Harrison, R., Barr, H., Moayyedi, P., AspECT Trial Team, 2018. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet, 392 (10145), 400-408.
  • Iveson, T.J., Kerr, R.S., Saunders, M.P., Cassidy, J., Hollander, N.H., Tabernero, J., Haydon, A., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Scudder, C., Boyd, K.A., Briggs, A., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., Dhadda, A.S., Harrison, M., Falk, S., Raouf, S., Rees, C., Olesen, R.K., Propper, D., Bridgewater, J., Azzabi, A., Farrugia, D., Webb, A., Cunningham, D., Hickish, T., Weaver, A., Gollins, S., Wasan, H.S., Paul, J., 2018. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19 (4), 562-578.
  • Pritchard, C., Williams, R., Hickish, T., Wallace, M., 2018. A Population-Based Study Comparing Child (0-4) and Adult (55-74) Mortality, GDP-Expenditure on-Health and Relative Poverty in the UK and Developed Countries 1989-2014. Some Challenging Outcomes. Archives of Community Medicine and Public Health, 3 (2), 77-84.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S., Cortés, J., 2018. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European Journal of Cancer, 89, 27-35.
  • McLaughlin, P., Mactier, H., Gillis, C., Hickish, T., Parker, A., Liang, W.J., Osselton, M.D., 2017. Increased DNA Methylation of ABCB1, CYP2D6, and OPRM1 Genes in Newborn Infants of Methadone-Maintained Opioid-Dependent Mothers. Journal of Pediatrics, 190, 180-184.e1.
  • Emile, J.F., Julié, C., Le Malicot, K., Lepage, C., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J.L., Dimet, S., Boulagnon-Rombi, C., Allard, M.A., Penault-Llorca, F., Bennouna, J., Laurent-Puig, P., Taieb, J., Thaler, J., Greil, R., Gaenzer, J., Eisterer, W., Tschmelitsch, J., Keil, F., Samonigg, H., Zabernigg, A., Schmid, F., Steger, G., Steinacher, R., Andel, J., Jagdt, B., Lang, A., Fridrik, M., Függer, R., Hofbauer, F., Woell, E., Geissler, D., Lenauer, A., Prager, M., D'Haens, G., Demolin, G., Kerger, J., Deboever, G., Ghillebert, G., Polus, M., Van Cutsem, E., Kalantari, H.R., Delaunoit, T., Goeminne, J.C., Peeters, M., Vergauwe, P., Houbiers, G., Humblet, Y., Janssens, J., Schrijvers, D., Vanderstraeten, E., Vermorken, J., Van Daele, D., Ferrante, M., Forget, F., Hendlisz, A., Yilmaz, M., Nielsen, S.E., Vestermark, L., Larsen, J., Zawadi, M.A., Bouche, O., Mineur, L., Bennouna-Louridi, J., Dourthe, L.M., Ychou, M., Boucher, E., Pezet, D., Desseigne, F., Ducreux, M., Texereau, P., Miglianico, L., Rougier, P., Fratte, S., Levache, C.B., Merrouche, Y., Ellis, S., Locher, C., Ramee, J.F., Garnier, C., Viret, F., Chauffert, B., Cojean-Zelek, I., Michel, P., Lecaille, C., Borel, C., Seitz, J.F., Smith, D., Lombard-Bohas, C., Andre, T., Gornet, J.M., Fein, F., Coulon-Sfairi, M.A., Kaminsky, M.C., Lagasse, J.P., Luet, D., 2017. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 82, 16-24.
  • Gligorov, J., Ataseven, B., Verrill, M., de Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., Pivot, X., Koroveshi, D., Bouzid, K., Casalnuovo, M., Cascallar, D., Korbenfeld, E.P., Bastick, P., Beith, J., Colosimo, M., Friedlander, M., Ganju, V., Green, M., Patterson, K., Redfern, A., Richardson, G., Ceric, T., Gordana, K., Beato, C.A., Ferrari, M., Hegg, R., Helena, V., Ismael, G.F., Lessa, A.E., Mano, M., Morelle, A., Nogueira, J.A., Timcheva, K., Tomova, A., Tsakova, M., Zlatareva-Petrova, A., Asselah, J., Assi, H., Brezden-Masley, C., Chia, S., Freedman, O., Harb, M., Joy, A.A., Kulkarni, S., Prady, C., Gaete, A.A.A., Matamala, L., Torres, R., Yanez, E., Franco, S., Urrego, M., Gugić, D., Vrbanec, D., Melichar, B., Prausová, J., Vyzula, R., Pilarte, R.G., León, M.I., Muñoz, R., Ramos, G., Azeem, H.A., Aziz, A.A., El Zawahry, H., Osegueda, F.R., Alexandre, J., Artignan, X., Barletta, H., Beguier, E., Berdah, J.F., Marty, C.B., Bollet, M., Bourgeois, H., Bressac, C., Burki, F., Campone, M., Coeffic, D., Cojocarasu, O.Z., Dagada, C., Dalenc, F., Del Piano, F., Desauw, C., Desmoulins, I., Dohollou, N., Egreteau, J., Ferrero, J.M., Foa, C., Garidi, R., Gasnault, L., Guardiola, E., Hamizi, S., Jarcau, R., Jacquin, J.P., Jaubert, D., Jolimoy, G., Mineur, H.L., Largillier, R., Leduc, B., 2017. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 82, 237-246.
  • Wasan, H.S., Gibbs, P., Sharma, N.K., Taieb, J., Heinemann, V., Ricke, J., Peeters, M., Findlay, M., Weaver, A., Mills, J., Wilson, C., Adams, R., Francis, A., Moschandreas, J., Virdee, P.S., Dutton, P., Love, S., Gebski, V., Gray, A., Bateman, A., Blesing, C., Brown, E., Chau, I., Cummins, S., Cunningham, D., Falk, S., Hadaki, M., Hall, M., Hickish, T., Hornbuckle, J., Lofts, F., Lowndes, S., Mayer, A., Metcalfe, M., Middleton, G., Montazeri, A., Muirhead, R., Polychronis, A., Purcell, C., Ross, P., Sharma, R.A., Sherwin, L., Smith, D., Soomal, R., Swinson, D., Walther, A., Wilson, G., Amin, P., Angelelli, B., Balosso, J., Beny, A., Bloomgarden, D., Boucher, E., Bruch, H.R., Bui, J., Burge, M., Cardaci, G., Carlisle, J., Chai, S., Chen, Y.J., Chevallier, P., Chuong, M., Clarke, S., Coveler, A., Craninx, M., Delanoit, T., Deleporte, A., Eliadis, P., Facchini, F., Ferguson, T., Ferrante, M., Frenette, G., Frick, J., Ganju, V., Garofalo, M., Geboes, K., Gehbauer, G., George, B., Geva, R., Gordon, M., Gregory, K., Gulec, S., Hannigan, J., van Hazel, G., Heching, N., Helmberger, T., Hendlisz, A., Hendrickx, K., Holtzman, M., Isaacs, R., Jackson, C., James, P., Kaiser, A., Karapetis, C., Kaubisch, A., Ko, Y.D., Kröning, H., Lammert, F., Liauw, W., Limentani, S., 2017. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, 18 (9), 1159-1171.
  • Earl, H.M., Hiller, L., Dunn, J.A., Blenkinsop, C., Grybowicz, L., Vallier, A.L., Gounaris, I., Abraham, J.E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J.M.S., Cameron, D.A., Provenzano, E., Thomas, J., Hayward, R.L., Henderson, I.C., Gianni, L., Brady, M.F., Pivot, X., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis trial. Annals of Oncology, 28 (8), 1817-1824.
  • Thomas, J.S.J., Provenzano, E., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.L., Gounaris, I., Abraham, J., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Caldas, C., Bartlett, J.M.S., Cameron, D.A., Hayward, R.L., Earl, H.M., 2017. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), 1069-1077.
  • Davidson, M., Chau, I., Cunningham, D., Khabra, K., Iveson, T., Hickish, T., Seymour, M., Starling, N., 2017. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 9 (8), 333-340.
  • Kurzrock, R., Hickish, T., Wyrwicz, L., André, T., Sarosiek, T., Kocsis, J., Nemecek, R., Wu, Q., Mohanty, P., Stecher, M., Simard, J., Dinarello, C., 2017. Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1). Annals of oncology : official journal of the European Society for Medical Oncology, 28.
  • Una Cidon, E., Alonso, P., Hickish, T., 2017. Sensitivity and specificity of DPD deficiency screening test to predict capecitabine serious toxicities. Annals of oncology : official journal of the European Society for Medical Oncology, 28.
  • Earl, H.M., Hiller, L., Howard, H.C., Dunn, J.A., Young, J., Bowden, S.J., McDermaid, M., Waterhouse, A.K., Wilson, G., Agrawal, R., O'Reilly, S., Bowman, A., Ritchie, D.M., Goodman, A., Hickish, T., McAdam, K., Cameron, D., Dodwell, D., Rea, D.W., Caldas, C., Provenzano, E., Abraham, J.E., Canney, P., Crown, J.P., Kennedy, M.J., Coleman, R., Leonard, R.C., Carmichael, J.A., Wardley, A.M., Poole, C.J., Collaborators, T.T., 2017. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. LANCET ONCOLOGY, 18 (6), 755-769.
  • Middleton, G., Palmer, D.H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., Evans, A., Shaw, V.E., Wadsley, J., Valle, J.W., Propper, D., Wasan, H., Falk, S., Cunningham, D., Coxon, F., Ross, P., Madhusudan, S., Wadd, N., Corrie, P., Hickish, T., Costello, E., Campbell, F., Rawcliffe, C., Neoptolemos, J.P., 2017. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, 18 (4), 486-499.
  • Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Kocsis, J., Nemecek, R., Rogowski, W., Lesniewski-Kmak, K., Petruzelka, L., Apte, R.N., Mohanty, P., Stecher, M., Simard, J., de Gramont, A., 2017. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, 18 (2), 192-201.
  • Pugh, S.A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J.W., O'Reilly, D.A., Siriwardena, A.K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O.J., Cunningham, D., Maughan, T.S., Bridgewater, J.A., Primrose, J.N., 2016. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 115 (4), 420-424.
  • Pritchard, C., Hickish, T., Rosenorn-Lanng, E., Wallace, M., 2016. Comparing UK and 20 Western countries' efficiency in reducing adult (55-74) cancer and total mortality rates 1989-2010: Cause for cautious celebration? A population-based study. JRSM Open, 7 (6), 2054270416635036.
  • Saunders, E.J., Dadaev, T., Leongamornlert, D.A., Al Olama, A.A., Benlloch, S., Giles, G.G., Wiklund, F., Gronberg, H., Haiman, C.A., Schleutker, J., Nordestgaard, B.G., Travis, R.C., Neal, D., Pasayan, N., Khaw, K.-T., Stanford, J.L., Blot, W.J., Thibodeau, S.N., Maier, C., Kibel, A.S., Cybulski, C., Cannon-Albright, L., Brenner, H., Park, J.Y., Kaneva, R., Batra, J., Teixeira, M.R., Pandha, H., Govindasami, K., Muir, K., UK Genetic Prostate Cancer Study Collaborators, UK ProtecT Study Collaborators, PRACTICAL Consortium, Easton, D.F., Eeles, R.A., Kote-Jarai, Z., 2016. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer, 114 (8), 945-952.
  • Ali, H.R., Dariush, A., Provenzano, E., Bardwell, H., Abraham, J.E., Iddawela, M., Vallier, A.L., Hiller, L., Dunn, J.A., Bowden, S.J., Hickish, T., McAdam, K., Houston, S., Irwin, M.J., Pharoah, P.D.P., Brenton, J.D., Walton, N.A., Earl, H.M., Caldas, C., 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1).
  • André, T., De Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J.L., Banzi, M., Maartense, E., Shmueli, E., Carlsson, G.U., Scheithauer, W., Papamichael, D., Möehler, M., Landolfi, S., Demetter, P., Colote, S., Tournigand, C., Louvet, C., Duval, A., Fléjou, J.F., De Gramont, A., 2015. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. Journal of Clinical Oncology, 33 (35), 4176-4187.
  • Sclafani, F., Peckitt, C., Cunningham, D., Tait, D., Giralt, J., Glimelius, B., Keränen, S.R., Bateman, A., Hickish, T., Tabernero, J., Thomas, J., Brown, G., Oates, J., Chau, I., 2015. Short- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C trial. International Journal of Radiation Oncology Biology Physics, 93 (2), 303-312.
  • Amin Al Olama, A., Dadaev, T., Hazelett, D.J., Li, Q., Leongamornlert, D., Saunders, E.J., Stephens, S., Cieza-Borrella, C., Whitmore, I., Benlloch Garcia, S., Giles, G.G., Southey, M.C., Fitzgerald, L., Gronberg, H., Wiklund, F., Aly, M., Henderson, B.E., Schumacher, F., Haiman, C.A., Schleutker, J., Wahlfors, T., Tammela, T.L., Nordestgaard, B.G., Key, T.J., Travis, R.C., Neal, D.E., Donovan, J.L., Hamdy, F.C., Pharoah, P., Pashayan, N., Khaw, K.-T., Stanford, J.L., Thibodeau, S.N., Mcdonnell, S.K., Schaid, D.J., Maier, C., Vogel, W., Luedeke, M., Herkommer, K., Kibel, A.S., Cybulski, C., Wokołorczyk, D., Kluzniak, W., Cannon-Albright, L., Brenner, H., Butterbach, K., Arndt, V., Park, J.Y., Sellers, T., Lin, H.-Y., Slavov, C., Kaneva, R., Mitev, V., Batra, J., Clements, J.A., Spurdle, A., Teixeira, M.R., Paulo, P., Maia, S., Pandha, H., Michael, A., Kierzek, A., Govindasami, K., Guy, M., Lophatonanon, A., Muir, K., Viñuela, A., Brown, A.A., PRACTICAL Consortium, COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative, Australian Prostate Cancer BioResource, UK Genetic Prostate Cancer Study Collaborators, UK ProtecT Study Collaborators, Freedman, M., Conti, D.V., Easton, D., Coetzee, G.A., Eeles, R.A., Kote-Jarai, Z., 2015. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet, 24 (19), 5589-5602.
  • Primrose, J.N., Cunningham, D., Garden, O.J., Maughan, T.S., Pugh, S.A., Stanton, L., Falk, S.J., Rees, M., Finch-Jones, M., Valle, J.W., O'Reilly, D., Hornbuckle, J., Hickish, T., Bridgewater, J.A., 2015. Cetuximab is contraindicated in the perioperative treatment of colorectal liver metastases. Journal of Clinical Oncology, 33 (21), 2405-2406.
  • Earl, H.M., Hiller, L., Dunn, J.A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., Gounaris, I., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D.A., Hayward, L., ARTemis Investigators, 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol, 16 (6), 656-666.
  • Earl, H., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., Gournaris, I., McAdam, K., Chan, S., Ahmad, R., Hickish T, Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D., Hayward, L., ARTemis investigators, 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncology.
  • Abbey, G., Thompson, S.B.N., Hickish, T., 2015. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. Psycho-Oncology, 24 (4), 371-381.
  • PETACC-8 study investigators, Thaler, J., Greil, R., Gaenzer, J., Eisterer, W., Tschmelitsch, J., Samonigg, H., Zabernigg, A., Schmid, F., Steger, G., Steinacher, R., Andel, J., Lang, A., Függer, R., Hofbauer, F., Woell, E., Geissler, D., Lenauer, A., Prager, M., Van Laethem, J.-L., Van Cutsem, E., D'Haens, G., Demolin, G., Kerger, J., Deboever, G., Ghillebert, G., Polus, M., Van Cutsem, E., RezaieKalantari, H., Delaunoit, T., Goeminne, J.C., Peeters, M., Vergauwe, P., Houbiers, G., Humblet, Y., Janssens, J., Schrijvers, D., Vanderstraeten, E., Van Laethem, J.-L., Vermorken, J., Van Daele, D., Ferrante, M., Forget, F., Hendlisz, A., Yilmaz, M., Nielsen, S.E., Vestermark, L., Larsen, J., Ychou, M., Zawadi, A., Zawadi, M.-A., Bouche, O., Mineur, L., Bennouna-Louridi, J., Dourthe, L.M., Ychou, M., Boucher, E., Taieb, J., Pezet, D., Desseigne, F., Ducreux, M., Texereau, P., Miglianico, L., Rougier, P., Fratte, S., Levache, C.-B., Merrouche, Y., Ellis, S., Locher, C., Ramee, J.-F., Garnier, C., Viret, F., Chauffert, B., Cojean-Zelek, I., Michel, P., Lecaille, C., Borel, C., Seitz, J.-F., Smith, D., Lombard-Bohas, C., Andre, T., Gornet, J.-M., Fein, F., Coulon-Sfairi, M.-A., Kaminsky, M.-C., Lagasse, J.-P., Luet, D., Etienne, P.-L., Gasmi, M., Vanoli, A., Nguyen, S., Aparicio, T., Perrier, H., Stremsdoerfer, N., Laplaige, P., Arsene, D., Auby, D., Bedenne, L., Coriat, R., Denis, B., Geoffroy, P., Piot, G., Becouarn, Y., Bordes, G., Deplanque, G., Dupuis, O., Fruge, F., Guimbaud, R., Lecomte, T., Lledo, G., Sobhani, I., Asnacios, A., Azzedine, A., Desauw, C., Galais, M.-P., Gargot, D., Lam, Y.-H., Abakar-Mahamat, A., Berdah, J.-F., Catteau, S., Clavero-Fabri, M.-C., Codoul, J.-F., Legoux, J.-L., Goldfain, D., Guichard, P., Verge, D.P., Provencal, J., Vedrenne, B., Brezault-Bonnet, C., Cleau, D., Desir, J.-P., Fallik, D., Garcia, B., Gaspard, M.-H., Genet, D., Hartwig, J., Krummel, Y., MatysiakBudnik, T., Palascak-Juif, V., Randrianarivelo, H., Rinaldi, Y., Aleba, A., Darut-Jouve, A., de Gramont, A., Hamon, H., Wendehenne, F., Matzdorff, A., Stahl, M.K., Schepp, W., Burk, M., Mueller, L., Folprecht, G., Geissler, M., Mantovani-Loeffler, L., Hoehler, T., Asperger, W., Kroening, H., von Weikersthal, L.F., Fuxius, S., Groschek, M., Meiler, J., Trarbach, T., Rauh, J., Ziegenhagen, N., Kretzschmar, A., Graeven, U., Nusch, A., von Wichert, G., Hofheinz, R.-D., Kleber, G., Schmidt, K.-H., Vehling-Kaiser, U., Baum, C., Schuette, J., Haag, G.M., Holtkamp, W., Potenberg, J., Reiber, T., Schliesser, G., Schmoll, H.-J., Schneider-Kappus, W., Abenhardt, W., Denzlinger, C., Henning, J., Marxsen, B., GuenterDerigs, H., Lambertz, H., Becker-Boost, I., Caca, K., Constantin, C., Decker, T., Eschenburg, H., Gabius, S., Hebart, H., Hoffmeister, A., Horst, H.-A., Kremers, S., Leithaeuser, M., Mueller, S., Wagner, S., Daum, S., Schlegel, F., Stauch, M., Heinemann, V., Labianca, R., Colucci, G., Amadori, D., Mini, E., Falcone, A., Boni, C., Maiello, E., Latini, L., Zaniboni, A., Amadori, D., Aprile, G., Barni, S., Mattioli, R., Martoni, A., Passalacqua, R., Nicolini, M., Pasquini, E., Rabbi, C., Aitini, E., Ravaioli, A., Barone, C., Biasco, G., Tamberi, S., Gambi, A., Verusio, C., Marzola, M., Lelli, G., Boni, C., Cascinu, S., Bidoli, P., Vaghi, M., Cruciani, G., Di Costanzo, F., Sobrero, A., Mini, E., Petrioli, R., Aglietta, M., Alabiso, O., Capuzzo, F., Falcone, A., Corsi, D.C., Labianca, R., Salvagni, S., Chiara, S., Ferraù, F., Giuliani, F., Lonardi, S., Gebbia, N., Mantovani, G., Sanches, E., Sanches, E., Mellidez, J.C., Santos, P., Freire, J., Sarmento, C., Costa, L., Pinto, A.M., Barroso, S., Santo, J.E., Guedes, F., Monteiro, A., Sa, A., Furtado, I., Tabernero, J., Salazar, R., Aguilar, E.A., Herrero, F.R., Tabernero, J., Valera, J.S., ValladaresAyerbes, M., FeliuBatlle, J., Gil, S., Garcia-Giron, C., Vivanco, G.L., Salvia, A.S., Orduña, V.A., Garcia, R.V., Gallego, J., Sureda, B.M., Remon, J., Safont Aguilera, M.J., CireraNogueras, L., Merino, B., Castro, C.G., de Prado, P.M., PijaumePericay, C., ConstenlaFigueiras, M., Jordan, I., GomeReina, M.J., Garcia, A.L.-L., Garcia-Ramos, A.A., Cervantes, A., Martos, C.F., MarcuelloGaspar, E., Montero, I.C., Emperador, P.E., Carbonero, A.L., Castillo, M.G., Garcia, T.G., Lopez, J.G., Flores, E.G., GuillotMorales, M., LlanosMuñoz, M., Martín, A.L., Maurel, J., Camara, J.C., Garcia, R.D., Salgado, M., HernandezBusquier, I., Ruiz, T.C., LacastaMuñoa, A., Aliguer, M., Ortiz de Taranco, A.V., Ureña, M.M., Gaspa, F.L., Ponce, J.J., Roig, C.B., Jimenez, P.V., GalanBrotons, A., AlbiolRodriguez, S., Martinez, J.A., Ruiz, L.C., CentellesRuiz, M., Bridgewater, J., Glynne-Jones, R., Tahir, S., Hickish, T., Cassidy, J., Samuel, L.. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol, 26 (4).
  • Purandare, L., Hickish, T.. Acceptability and safety of telemedicine to assess patients before chemotherapy. Cancer Nursing Practice, 14 (6).
  • Gillis, C., McLaughlin, P., Osselton, D., Hickish, T., Mactier, H.. Genetic and epigenetic variations and gene methylation in infants exposed to methadone in-utero. British Association of Perinatal Medicine; Arch Dis Child.
  • Sclafani, F., Peckitt, C., Cunningham, D., Tait, D., Giralt, J., Glimelius, B., Keränen, S.R., Bateman, A., Hickish, T., Tabernero, J., Thomas, J., Brown, G., Oates, J., Chau, I., 2014. Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. International Journal of Radiation Oncology Biology Physics.
  • Mishu, M., Dubey, V.N., Hickish, TH, Cole, J., 2014. A Review on Pressure Ulcer: Aetiology, Cost, Detection and Prevention Systems. International Journal of Engineering Sciences & Research Technology, 3 (9), 419-428.
  • Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Robinson, A., McAdam, K., Eatock, M., Evans, J., Archer, C., Hickish, T., Garcia-Alonso, A., Nicolson, M., Steward, W., Anthoney, A., Greenhalf, W., Shaw, V., Costello, E., Naisbitt, D., Rawcliffe, C., Nanson, G., Neoptolemos, J., 2014. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol, 15 (8), 829-840.
  • Taieb, J., Tabernero, J., Mini, E., Subtil, F., Folprecht, G., Van Laethem, J.-L., Thaler, J., Bridgewater, J., Petersen, L.N., Blons, H., Collette, L., Van Cutsem, E., Rougier, P., Salazar, R., Bedenne, L., Emile, J.-F., Laurent-Puig, P., Lepage, C., PETACC-8 Study Investigators, 2014. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol, 15 (8), 862-873.
  • Masters, B., Hickish, T., Cidon, E.U., 2014. A midline for oxaliplatin infusion: the myth of safety devices. BMJ Case Rep, 2014.
  • Mishu, M.C., Dubey, V.N., Hickish, T., Cole, J., 2014. Mathematical Modelling of Different Types of Body Support Surface for Pressure Ulcer Prevention. International Journal of Medical, Pharmaceutical Science and Engineering, 8 (5), 209-214.
  • Yao, C., Nash, G.F., Hickish, T., 2014. Management of colorectal cancer and diabetes. J R Soc Med, 107 (3), 103-109.
  • Molife, L.R., Omlin, A., Jones, R.J., Karavasilis, V., Bloomfield, D., Lumsden, G., Fong, P.C., Olmos, D., O'Sullivan, J.M., Pedley, I., Hickish, T., Jenkins, P., Thompson, E., Oommen, N., Wheatley, D., Heath, C., Temple, G., Pelling, K., de Bono, J.S., 2014. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol, 10 (2), 219-231.
  • Earl, H.M., Vallier, A.-L., Hiller, L., Fenwick, N., Young, J., Iddawela, M., Abraham, J., Hughes-Davies, L., Gounaris, I., McAdam, K., Houston, S., Hickish, T., Skene, A., Chan, S., Dean, S., Ritchie, D., Laing, R., Harries, M., Gallagher, C., Wishart, G., Dunn, J., Provenzano, E., Caldas, C., Neo-tAnGo Investigators, 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol, 15 (2), 201-212.
  • Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., Hornbuckle, J., Peterson, M., Rees, M., Iveson, T., Hickish, T., Butler, R., Stanton, L., Dixon, E., Little, L., Bowers, M., Pugh, S., Garden, O.J., Cunningham, D., Maughan, T., Bridgewater, J., 2014. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncology, 15 (6), 601-611.
  • Pan, J.J., Chang, J., Yang, X., Zhang, J.J., Qureshi, T., Howell, R., Hickish, T., Liang, H., 2014. Virtual reality training and assessment in laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery.
  • Hickish, T., Cassidy, J., Propper, D., Chaud, I., Falke, S., Ford, H., Iveson, T., Braun, M., Potter, V., Macpherson, I., Finnigan, H., Leek, C., Jones, H., Harrison, M., 2014. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50, 3136-3144.
  • Wasan, H., Meade, A.M., Adams, R., Wilson, R., Pugh, C., Fisher, D., Sydes, B., Madi, A., Sizer, B., Lowdell, C., Middleton, G., Butler, R., Kaplan, R., Maughan, T., 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, 15 (6), 631-639.
  • Hickish, T., Cassidy, J., Propper, D., Chaud, I., Falke, S., Ford, H., Iveson, T., Braun, M., Potter, V., Macpherson, I., Finnigan, H., Leek, C., Jones, H., Harrison, M.. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50.
  • Awada, A., Spector, N., El-Hariry, I., Rodriguez, A.A., Erban, J.K., Cortes, J., Gomez, H., Kong, A., Hickish, T., Fein, L., Vahdat, L., MacPherson, I., Canon, J.-L., Mansoor, S., Giovanne, A., McAdam, K., Vukovic, V.M., Yalcin, I., Bradley, R., Proia, D., Mano, M.S., Perez, E.A., Cameron, D.A., 2013. The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative obreast cancer (TNBC). CANCER RESEARCH, 73.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J.H., Tsai, Y.-F., Ratnayake, J., McNally, V., Ross, G., Cortés, J., 2013. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 24 (9), 2278-2284.
  • Agbamu, D.A., Day, N., Walsh, C.J., Hendrickse, C.W., Langman, G., Pallan, A., Lowe, A., Ostrowski, J., Steward, M., Callaway, M., Falk, S., Thomas, M.G., Wong, N., Hartley, J., MacDonald, A.W., Blunt, D., Cohen, P., Dawson, P., Lowdell, C.P., Furniss, D., Gupta, R., Taraporewalla, R.D., Braun, M., Cruickshank, N., Muzaffar, S., Smith, D., Daniel, F., Denson, J., Jackson, S., Sleigh, K., Kweka, E., Pearson, H.J., Peters, M., Roy, R., Kurien, G., Robinson, J., Wadsley, J., White, D., Lamparelli, M.J., Mikel, J., Osborne, R., Taylor, P., Ilesley, I.C., Moran, B.J., O'Neill, H., Rees, C., Buxton, A., Harrison, J., Last, K., Scullion, D., Dent, J., Hyde, J., Ilsley, D., Raja, U., Roberts, C., Crabtree, M., Orrell, J., Smith, S., Soomal, R., Hill, J., Howarth, G., Lee, S., Church, R., Hartley, A., Holland, C., Thompson, A.K., Glynne-Jones, R., Livingstone, J., Richman, P., Train, M., Barlow, C., Burn, P., Geraghty, J., Vickery, C.J., Walther, J., Grumett, S., Mangalika, S.A.M., Qaiyum, M., Williams, G., Borgstein, R., Bridgewater, J.A., Meleagros, L., Rees, J.A., Needham, S.J., Scott, J., Anathhanam, A., Brittenden, J., Macklin, C., Swinson, D., Alexander, J., Hickish, T.F.G., Talbot, R.W., Tarver, D., Lalude, O., Partridge, W., Sundaresan, V., Cowlishaw, D., Higginson, A., Muthuramalingam, S.R., 2012. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. Lancet Oncology, 13 (11), 1152-1160.
  • Hickish, T., Farmery, A.D., 2012. Acid-base physiology: New concepts. Anaesthesia and Intensive Care Medicine, 13 (11).
  • Nash, G.F., Turner, K.J., Hickish, T., Smith, J., Chand, M., Moran, B.J., 2012. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl, 94 (7), 456-462.
  • Tournigand, C., André, T., Bonnetain, F., Chibaudel, B., Lledo, G., Hickish, T., Tabernero, J., Boni, C., Bachet, J.-B., Teixeira, L., de Gramont, A., 2012. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol, 30 (27), 3353-3360.
  • Dunlop, M.G., Dobbins, S.E., Farrington, S.M., Jones, A.M., Palles, C., Whiffin, N., Tenesa, A., Spain, S., Broderick, P., Ooi, L.Y., Domingo, E., Smillie, C., Henrion, M., Frampton, M., Martin, L., Grimes, G., Gorman, M., Semple, C., Ma, Y.P., Barclay, E., Prendergast, J., Cazier, J.B., Olver, B., Penegar, S., Lubbe, S., Chander, I., Carvajal-Carmona, L.G., Ballereau, S., Lloyd, A., Vijayakrishnan, J., Zgaga, L., Rudan, I., Theodoratou, E., Thomas, H., Maher, E., Evans, G., Walker, L., Halliday, D., Lucassen, A., Paterson, J., Hodgson, S., Homfray, T., Side, L., Izatt, L., Donaldson, A., Tomkins, S., Morrison, P., Brewer, C., Henderson, A., Davidson, R., Murday, V., Cook, J., Haites, N., Bishop, T., Sheridan, E., Green, A., Marks, C., Carpenter, S., Broughton, M., Greenhalge, L., Suri, M., Starr, J.M., Deary, I., Kirac, I., Kovacevia, D., Aaltonen, L.A., Renkonen-Sinisalo, L., Mecklin, J.P., Matsuda, K., Nakamura, Y., Okada, Y., Gallinger, S., Duggan, D.J., Conti, D., Newcomb, P., Hopper, J., Jenkins, M.A., Schumacher, F., Casey, G., Easton, D., Shah, M., Pharoah, P., Lindblom, A., Liu, T., Edler, D., Lenander, C., Dalén, J., Hjern, F., Lundqvist, N., Lindforss, U., Påhlman, L., Smedh, K., Törnqvist, A., Holm, J., Janson, M., Andersson, M., Ekelund, S., Olsson, L., Smith, C.G., West, H., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44 (7), 770-776.
  • Lin, N.U., Winer, E.P., Wheatley, D., Carey, L.A., Houston, S., Mendelson, D., Munster, P., Frakes, L., Kelly, S., Garcia, A.A., Cleator, S., Uttenreuther-Fischer, M., Jones, H., Wind, S., Vinisko, R., Hickish, T., 2012. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 133 (3), 1057-1065.
  • Dunlop, M.G., Dobbins, S.E., Farrington, S.M., Jones, A.M., Palles, C., Whiffin, N., Tenesa, A., Spain, S., Broderick, P., Ooi, L.-Y., Domingo, E., Smillie, C., Henrion, M., Frampton, M., Martin, L., Grimes, G., Gorman, M., Semple, C., Ma, Y.P., Barclay, E., Prendergast, J., Cazier, J.-B., Olver, B., Penegar, S., Lubbe, S., Chander, I., Carvajal-Carmona, L.G., Ballereau, S., Lloyd, A., Vijayakrishnan, J., Zgaga, L., Rudan, I., Theodoratou, E., Colorectal Tumour Gene Identification (CORGI) Consortium, Starr, J.M., Deary, I., Kirac, I., Kovacević, D., Aaltonen, L.A., Renkonen-Sinisalo, L., Mecklin, J.-P., Matsuda, K., Nakamura, Y., Okada, Y., Gallinger, S., Duggan, D.J., Conti, D., Newcomb, P., Hopper, J., Jenkins, M.A., Schumacher, F., Casey, G., Easton, D., Shah, M., Pharoah, P., Lindblom, A., Liu, T., Swedish Low-Risk Colorectal Cancer Study Group, Smith, C.G., West, H., Cheadle, J.P., COIN Collaborative Group, Midgley, R., Kerr, D.J., Campbell, H., Tomlinson, I.P., Houlston, R.S., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet, 44 (7), 770-776.
  • Moyers-Ruiz, L., Hickish, T., Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 ((Suppl), abstr).
  • James, N.D., Hussain, S.A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., Lewis, R., Waters, R., Huddart, R.A., BC2001 Investigators, 2012. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med, 366 (16), 1477-1488.
  • Moyers-Ruiz, L., Thompson, S., Hickish, T., 2012. Investigation Of Prospective And Working Memory Decline And The Impact Of Impaired Sleep And/Or Glucose Metabolism In Recently Diagnosed Breast Cancer Patients Undergoing Chemotherapy: A Longitudinal Study. PSYCHO-ONCOLOGY, 21, 6.
  • Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., Aktan, G., Goldhirsch, A., Chang, T.-W., Horváth, Z., Coccia-Portugal, M., Domont, J., Tseng, L.-M., Kunz, G., Sohn, J.H., Semiglazov, V., Lerzo, G., Palacova, M., Probachai, V., Pusztai, L., Untch, M., Gelber, R.D., Piccart-Gebhart, M., NeoALTTO Study Team, 2012. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379 (9816), 633-640.
  • Moyers-Ruiz, L., Hickish, T., Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 (Suppl).
  • Chirgwin, J., Sun, Z., Smith, I., Price, K.N., Thürlimann, B., Ejlertsen, B., Bonnefoi, H., Regan, M.M., Goldhirsch, A., Coates, A.S., BIG 1-98 Collaborative and International Breast Cancer Study Groups, 2012. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat, 131 (1), 295-306.
  • Schroeder, J., Dubey, V., Hickish, T., Cole, J.. Wearable Electrocutaneous Feedback System: A Smart Device to Compensate for Sensation Loss. Journal of Medical Devices, 6 (1).
  • Schroeder, J., Dubey, V., Hickish, T., Cole, J.. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. Journal of Medical Devices, 6 (1).
  • Regan, M.M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J.F., Smith, I., Láng, I., Wardley, A., Rabaglio, M., Price, K.N., Gelber, R.D., Coates, A.S., Thürlimann, B., BIG 1-98 Collaborative Group, International Breast Cancer Study Group (IBCSG), 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol, 12 (12), 1101-1108.
  • Thompson, S., Eccleston, L., Hickish, T.F., 2011. Post-traumatic stress disorder on cancer survivors: recognising and acknowledging the symptoms. WMC Oncology, 2.
  • Adams, R.A., Meade, A.M., Seymour, M.T., Wilson, R.H., Madi, A., Fisher, D., Kenny, S.L., Kay, E., Hodgkinson, E., Pope, M., Rogers, P., Wasan, H., Falk, S., Gollins, S., Hickish, T., Bessell, E.M., Propper, D., Kennedy, M.J., Kaplan, R., Maughan, T.S., MRC COIN Trial Investigators, 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol, 12 (7), 642-653.
  • Maughan, T.S., Adams, R.A., Smith, C.G., Meade, A.M., Seymour, M.T., Wilson, R.H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S.L., Kay, E., Mitchell, J.K., Madi, A., Jasani, B., James, M.D., Bridgewater, J., Kennedy, M.J., Claes, B., Lambrechts, D., Kaplan, R., Cheadle, J.P., MRC COIN Trial Investigators, 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, 377 (9783), 2103-2114.
  • Seymour, M.T., Thompson, L.C., Wasan, H.S., Middleton, G., Brewster, A.E., Shepherd, S.F., O'Mahony, M.S., Maughan, T.S., Parmar, M., Langley, R.E., FOCUS2 Investigators, National Cancer Research Institute Colorectal Cancer Clinical Studies Group, 2011. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet, 377 (9779), 1749-1759.
  • Seymour, M.T., Brown, S.R., Richman, S., Middleton, G.W., Maughan, T., Olivier, C., Gwyther, S.J., Wadsley, J., Chau, I., Hickish, T., Dawson, L.K., Falk, S., O'Callaghan, A., Benstead, K., Wadd, N., Oliver, A., Chambers, P., Marshall, H., Napp, V., Quirke, P., UK NCRI Colorectal Clinical Studies Group, 2011. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J Clin Oncol, 29 (15_suppl).
  • Pritchard, C., Hickish, T.F., 2011. Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK. Lancet, 377, 1149.
  • Pritchard, C., Hickish, T.F., 2011. Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006. British Journal of Cancer.
  • Pan, J., Chang, J., Yang, X., Zhang, J.J., Qureshi, T., Howell, R.. A Medical VR Simulator in Laparoscopic Rectum Surgery. Cyber Therapy and Rehabilitation, 4.
  • Teixeira, L., Hickish, T., Tournigand, C., Bachet, J., Bonetti, A., Rivera, F., Boni, C., Tabernero, J., Andre, T., De Gramont, A., 2010. Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • Toumigand, C., Andre, T., Bachet, J., Teixeira, L., Boni, C., Clingan, P.R., Hickish, T., Tabernero, J., De Gramont, A., 2010. FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S.P., Roughton, M., Bridgewater, J., ABC-02 Trial Investigators, 2010. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362 (14), 1273-1281.
  • Houston, S., Grieve, R.J., Hickish, T.F., Percival, F., Hamilton, E., 2010. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. Journal of Medical Economics, 13, 162-167.
  • Sirohi, B., A'Hern, R.P., Coombes, G.A., Bliss, J.M., Hickish, T.F., Perren, T.J., Crawford, M., O'Brien, M., Iveson, T., Ebbs, S.R., Skene, A.I., Laing, R., Smith, I.E., 2010. A randomized comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Annals of Oncology, 21, 1623-1629.
  • Cunningham, D., Hickish, T.F., 2010. A multicentre phase II study of capecitabine, oxaliplatin plus bevacizumab as peri-operative treatment for patients with poor risk colorectal liver-only metastases unsuitable for upfront resection. Journal of Clinical Oncology.
  • Pan, J., Chang, J., Yang, X., Zhang, J., Qureshi, T., Howell, R.D., Hickish, T.F., 2010. Graphic and haptic simulation system for virtual laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery, 7.
  • Al Olama, A.A., Kote-Jarai, Z., Giles, G.G., Guy, M., Morrison, J., Severi, G., Leongamornlert, D.A., Tymrakiewicz, M., Jhavar, S., Saunders, E., Hopper, J.L., Southey, M.C., Muir, K.R., English, D.R., Dearnaley, D.P., Ardern-Jones, A.T., Hall, A.L., O'Brien, L.T., Wilkinson, R.A., Sawyer, E., Lophatananon, A., UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich, A., Huddart, R.A., Khoo, V.S., Parker, C.C., Woodhouse, C.J., Thompson, A., Christmas, T., Ogden, C., Cooper, C., Donovan, J.L., Hamdy, F.C., Neal, D.E., Eeles, R.A., Easton, D.F., 2009. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet, 41 (10), 1058-1060.
  • Eeles, R.A., Kote-Jarai, Z., Al Olama, A.A., Giles, G.G., Guy, M., Severi, G., Muir, K., Hopper, J.L., Henderson, B.E., Haiman, C.A., Schleutker, J., Hamdy, F.C., Neal, D.E., Donovan, J.L., Stanford, J.L., Ostrander, E.A., Ingles, S.A., John, E.M., Thibodeau, S.N., Schaid, D., Park, J.Y., Spurdle, A., Clements, J., Dickinson, J.L., Maier, C., Vogel, W., Dörk, T., Rebbeck, T.R., Cooney, K.A., Cannon-Albright, L., Chappuis, P.O., Hutter, P., Zeegers, M., Kaneva, R., Zhang, H.-W., Lu, Y.-J., Foulkes, W.D., English, D.R., Leongamornlert, D.A., Tymrakiewicz, M., Morrison, J., Ardern-Jones, A.T., Hall, A.L., O'Brien, L.T., Wilkinson, R.A., Saunders, E.J., Page, E.C., Sawyer, E.J., Edwards, S.M., Dearnaley, D.P., Horwich, A., Huddart, R.A., Khoo, V.S., Parker, C.C., Van As, N., Woodhouse, C.J., Thompson, A., Christmas, T., Ogden, C., Cooper, C.S., Southey, M.C., Lophatananon, A., Liu, J.-F., Kolonel, L.N., Le Marchand, L., Wahlfors, T., Tammela, T.L., Auvinen, A., Lewis, S.J., Cox, A., FitzGerald, L.M., Koopmeiners, J.S., Karyadi, D.M., Kwon, E.M., Stern, M.C., Corral, R., Joshi, A.D., Shahabi, A., McDonnell, S.K., Sellers, T.A., Pow-Sang, J., Chambers, S., Aitken, J., Gardiner, R.A.F., Batra, J., Kedda, M.A., Lose, F., Polanowski, A., Patterson, B., Serth, J., Meyer, A., Luedeke, M., Stefflova, K., Ray, A.M., Lange, E.M., Farnham, J., Khan, H., Slavov, C., Mitkova, A., Cao, G., UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, PRACTICAL Consortium, Easton, D.F., 2009. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet, 41 (10), 1116-1121.
  • BIG 1-98 Collaborative Group, Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thürlimann, B., Paridaens, R., Smith, I., Mauriac, L., Forbes, J.F., Price, K.N., Regan, M.M., Gelber, R.D., Coates, A.S., 2009. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med, 361 (8), 766-776.
  • Giobbie-Hurder, A., Price, K.N., Gelber, R.D., International Breast Cancer Study Group, BIG 1-98 Collaborative Group, 2009. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials, 6 (3), 272-287.
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H., Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. J Clin Oncol, 27 (15_suppl).
  • Earl, H.M., Vallier, A., Hiller, L., Fenwick, N., Iddawela, M., Hughes-Davies, L., Provenzano, E., McAdam, K., Hickish, T., Caldas, C., for NeotAnGo Investigators, 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). J Clin Oncol, 27 (15_suppl).
  • Ellis, P., Barrett-Lee, P., Johnson, L., Cameron, D., Wardley, A., O'Reilly, S., Verrill, M., Smith, I., Yarnold, J., Coleman, R., Earl, H., Canney, P., Twelves, C., Poole, C., Bloomfield, D., Hopwood, P., Johnston, S., Dowsett, M., Bartlett, J.M.S., Ellis, I., Peckitt, C., Hall, E., Bliss, J.M., TACT Trial Management Group, TACT Trialists, 2009. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet, 373 (9676), 1681-1692.
  • Chau, I., Norman, A.R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M., Hickish, T., 2009. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol, 20 (5), 885-891.
  • Hickish, T.F., Astras, G., Thomas, P., Penfold, S., Purandare, L., Kerr, D., 2009. Glucose intolerance during adjuvant chemotherapy for breast cancer. Correspondence. Journal of the National Cancer Institute, 101, 537.
  • Andre, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T.F., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., De Gramont, A., 2009. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II / III colon cancer: update from a randomised controlled trial. Journal of Clinical Oncology, 27, 3109-3116.
  • Boni, C., Andre, T., Banzi, M.C., Hickish, T.F., Tabernero, J., Clingan, P., Chibaudel, B., De Gramont, A.. Similarities and differences between the adjuvant oxaliplatin-based trials, MOSAIC and NSABP C-07. Current Colorectal Cancer Reports, 5.
  • Viale, G., Giobbie-Hurder, A., Regan, M.M., Coates, A.S., Mastropasqua, M.G., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S.G., Ohlschlegel, C., Neven, P., Orosz, Z., Olszewski, W.P., Knox, F., Thürlimann, B., Price, K.N., Castiglione-Gertsch, M., Gelber, R.D., Gusterson, B.A., Goldhirsch, A., Breast International Group Trial 1-98, 2008. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol, 26 (34), 5569-5575.
  • Pritchard, C., Hickish, T.F., 2008. Changes in Cancer Incidence and Mortality in England & Wales and a comparison of cancer deaths in the Major Developed Countries by Age and Sex 1979-2002 in context of GDP Expenditure on Health. ecancermedicalscience, 2, 1-18.
  • Hemandas, A.K., Robson, N.K., Hickish, T.F., Talbot, R.W., 2008. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Disease, 10, 386-389.
  • Chand, M., Moore, P.J., Clarke, A.D., Nash, G.F., Hickisk, T., 2007. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - A case report of primary papillary serous carcinoma presenting as sigmoid cancer. World Journal of Surgical Oncology, 5.
  • Hickish, T., Chau, I., Massey, A., Higgins, L., Osborne, R., Botwood, N., Swaisland, A., Cunningham, D.C., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy. J Clin Oncol, 24 (18_suppl).
  • Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G., Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol, 24 (18_suppl).
  • Chau, I., Cunningham, D., Russell, C., Norman, A.R., Kurzawinski, T., Harper, P., Harrison, P., Middleton, G., Daniels, F., Hickish, T.F., Prendeville, J., Ross, P.J., Theis, B., Hull, R., Walker, M., Shankley, N., Kalindjian, B., Murray, G., Gillbanks, A., Black, J., 2006. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 94, 1107-1115.
  • Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M.T.J., Harper, P., Iveson, T.J., Nicolson, M.C., Hickish, T.F., 2006. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. European Journal of Cancer, 42, 827-834.
  • Hickish, T.F.. Administration of cetuximab in managing colorectal cancer. Cancer Nursing Practice, 5.
  • Chau, I., Cunningham, D., Hickish, T.F., Massey, A., Higgins, L., Osborne, R.J., Botwood, N., Swaisland, A., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Annals of Oncology, 18, 730-737.
  • Chau, I., Norman, A.R., Cunningham, D., Iveson, T.J., Hill, M.E.E., Hickish, T.F., Lofts, F., Jodrell, D., Webb, A., Tait, D., Ross, P.J., Shellitoa, P., Oates, J.R., 2005. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer, 41, 1551-1559.
  • Chua, S., Smith, E., AHern, R.P., Coombes, G.A., Hickish, T.F., Robinson, A.C., Laing, R.W., O'Brien, M.E.R., Ebbs, S.R., Hong, A., Wardley, A., Mughal, T., Verrill, M., Dubois, D., Bliss, J.M., 2005. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Annals of Oncology, 16, 1435-1441.
  • Sumpter, K., Harper-Wynne, C., Cunningham, D., Rao, S., Tebbutt, N.C., Norman, A.R., Ward, C., Iveson, T.J., Nicolson, M.C., Hickish, T.F., Hill, M.E.E., Oates, J.R., 2005. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British Journal of Cancer, 92, 1976-1983.
  • Chau, I., Norman, A.R., Cunningham, D., Tait, D., Ross, P.J., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Webb, A., Oates, J.R., 2005. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol, 16 (4), 549-557.
  • Mandalà, M., Ferretti, G., Barni, S., De Gramont, A., André, T., Hickish, T., 2004. Oxaliplatin in colon cancer [3] (multiple letters). New England Journal of Medicine, 351 (16), 1691-1692.
  • Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. J Clin Oncol, 22 (14_suppl).
  • Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M., Hickish, T., 2004. Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. J Clin Oncol, 22 (14_suppl).
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T., De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. J Clin Oncol, 22 (14_suppl).
  • Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J., Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). J Clin Oncol, 22 (14_suppl).
  • Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T.F., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., Tabah-Fisch, I., de Gramont, A., 2004. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine, 350, 2343-2351.
  • Papazisis, K.T., Habeshaw, T., Miles, D.W., Leonard, R., Jones, A., Twelves, C., Coleman, R., Makris, A., Earl, H., Highley, M., Price, C., McKinna, F., Perren, T., Le Vay, J., McAleer, A., Houston, S., Crawford, M., Johnston, S., Howell, A., Wardley, A., Harris, A., O'Reilly, S., O'Byrne, K., Verrill, M., Hickish, T., Mansi, J.L., Barrett-Lee, P.J., Davidson, N., Stein, R., Rowland, C., Symmonds, P., Bailey, N., Chan, S., Soukop, M., 2004. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 58 (6), 581-586.
  • Smith, I.E., A'Hern, R.P., Coombes, G.A., Howell, A., Ebbs, S.R., Hickish, T.F., O Brien, M.E.R., Mansi, J.L., Wilson, C.B., Robinson, A.C., Murray, P.A., Price, C.G.A., Perren, T.J., Laing, R.W., Bliss, J.M., 2004. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology, 15, 751-758.
  • O'Brien, M.E.R., Anderson, H., Kaukel, E., O'Byrne, K., Pawlicki, M., von Pawel, J., Reck, M., Ellis, P., Hickish, T., Nicolson, M., Woll, P., Dunlop, D., Falk, S., Johnson, P., Collinson, M., Hatton, M., Gilligan, D., Middleton, G., Loddenkemper, R., Deperman, K., Aigner, K., Pirker, R., Rothmund, J., Tujakowski, J., Krzakowski, M., Ramlau, R., Crawford, B., Massaro, J., Cross, A., Tuckwell, N., Kennard, D., Povey, J., 2004. SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Annals of Oncology, 15 (6), 906-914.
  • Price, T.J., Ross, P.J., Hickish, T.F., Tait, D., Norman, A.R., Ford, H.E.R., Middleton, G., Sumpter, K., Hill, M.E.E., Oates, J.R., Cunningham, D., 2004. Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. Clinical Colorectal Cancer, 3, 235-242.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Bonetti, A., Clingan, P., Figer, A., Andre, T., de Gramont, A., 2004. Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis. ANNALS OF ONCOLOGY, 15, 76.
  • Ross, P.J., Trumper, M., Norman, A.R., Hawkins, R., Seymour, M., Harper, P.G., Iveson, T., Nicolson, M., Hickish, T., Cunningham, D., 2004. An analysis of the outcome to palliative chemotherapy for oesophagogastric (OGC) cancer in patients aged 70 years and older (≥70) with younger patients. ANNALS OF ONCOLOGY, 15, 230.
  • de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Marceau-Suissa, J., Andre, T., 2004. Oxaliplatin/5FU/LV in stage II and III Colon Cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial. ANNALS OF ONCOLOGY, 15, 73.
  • Moffat, A.C., Osselton, M.D., Widdop, B., Clarke, E.G.C.. Clarke's analysis of drugs and poisons. Pharmaceutical Pr.
  • Saini, A., Norman, A.R., Cunningham, D., Chau, I., Hill, M.E.E., Tait, D., Hickish, T.F., Iveson, T.J., Lofts, F., Jodrell, D., Ross, P.J., Oates, J.R., 2003. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. British Journal Of Cancer, 88, 1859-1866.
  • Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T.J., Seymour, M.T.J., Hickish, T.F., Massey, A., Prior, Y., Hilla, M.E., 2003. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer, 39, 1121-1128.
  • Johnston, S.R.D., Hickish, T.F., Ellis, P., Houston, S., Kelland, L., Dowsett, M., Salter, J., Michiels, B., Perez-Ruixo, J.J., Palmer, P., Howes, A., 2003. Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer. Journal of Clinical Oncology, 21, 2492-2499.
  • Maisey, N.R., Chau, I., Cunningham, D., Norman, A.R., Seymour, M.T.J., Hickish, T.F., Iveson, T.J., O Brien, M.E.R., Tebbutt, N.C., Harrington, A., Hill, M.E.E., 2002. Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. Journal of Clinical Oncology, 20, 3130-3136.
  • Tebbutt, N.C., Norman, A., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Harper, P., Maisey, N., Mochlinski, K., Prior, Y., Hill, M., 2002. A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Annals of Oncology, 13 (10), 1568-1575.
  • Ross, P.J., Nicolson, M.C., Cunningham, D., Valle, J., Seymour, M.T.J., Harper, P., Price, T.J., Anderson, H., Iveson, T.J., Hickish, T.F., Lofts, F., Norman, A., 2002. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 20, 1996-2004.
  • Dowsett, M., Cuzick, J., Howell, A., Jackson, I., ATAC Trialists' Group, 2001. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer, 85 (3), 317-324.
  • Donnelly, J., Parham, D.M., Hickish, T.F., Chan, H.Y., Skene, A.I., 2001. Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer. The Breast, 10, 61-66.
  • Smith, I.E., O Brien, M.E.R., Talbot, D.C., Nicolson, M.C., Mansi, J.L., Hickish, T.F., Norton, A., Ashley, S., 2001. Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin. Journal of Clinical Oncology, 19, 1336-1343.
  • Smith, I.E., A'Hern, R.P., Ebbs, S., Howell, A., Hickish, T., O'Brien, M., Robinson, A., Wilson, C., 2000. Preoperative continuous infusional (epirubicin, cisplatin and infusional 5 FU) v. conventional AC chemotherapy for early breast cancer: As phase III randomised trial. BRITISH JOURNAL OF CANCER, 83, 2.
  • Smith, I.E., Johnston, S.R.D., O Brien, M.E.R., Hickish, T.F., de Boer, R.H., Norton, A., Cirkel, D.T., Barton, C.M., 2000. Low-Dose Oral Fluorouracil With Eniluracil as First-Line Chemotherapy Against Advanced Breast Cancer: A Phase II Study. Journal of Clinical Oncology, 18, 2378-2384.
  • Iveson, T.J., Hickish, T., Schmitt, C., Van Cutsem, E., 1999. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer, 35 (13), 1796-1804.
  • Ross, P., Cunningham, D., Scarffe, H., Nicolson, M., Seymour, M., Harper, P., Price, T., Hill, A., Anderson, H., Iveson, T., Hickish, T., Lofts, F., Norman, A., 1999. Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. EUROPEAN JOURNAL OF CANCER, 35, S137.
  • Price, T., Cunningham, D., Hickish, T., Tait, D., Norman, A., Ross, P.J., Middleton, G., Ford, H.E.R., Sumpter, K., Hill, M., 1999. Dose intensification of 5 fluorouracil by chronomodulation in a phase III trial for advanced colorectal carcinoma. BRITISH JOURNAL OF CANCER, 80, 20.
  • Waters, J.S., Norman, A., Cunningham, D., Scarffe, J.H., Webb, A., Harper, P., Joffe, J.K., Mackean, M., Mansi, J., Leahy, M., Hill, A., Oates, J., Rao, S., Nicolson, M., Hickish, T., 1999. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer, 80 (1-2), 269-272.
  • Middleton, G.W., Smith, I.E., O'Brien, M.E.R., Norton, A., Hickish, T., Priest, K., Spencer, L., 1998. Good symptom relief with palliative MVP mitomycin-C, vinblastine and cisplatin chemotherapy in malignant mesothelioma. Pneumologie, 52 (7).
  • Makris, A., Powles, T.J., Ashley, S.E., Chang, J., Hickish, T., Tidy, V.A., Nash, A.G., Ford, H.T., 1998. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol, 9 (11), 1179-1184.
  • Cunningham, D., Pyrhönen, S., James, R.D., Punt, C.J.A., Hickish, T.F., Heikkila, R., Johannesen, T.B., Starkhammar, H., Topham, C.A., Awad, L., Jacques, C., Herait, P., 1998. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352 (9138), 1413-1418.
  • Cunningham, D., Powles, R., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hickish, T., Nicolson, M., Johnson, P., Treleaven, J., Raymond, J., Gore, M., 1998. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol, 102 (2), 495-502.
  • Middleton, G.W., Smith, I.E., O'Brien, M.E., Norton, A., Hickish, T., Priest, K., Spencer, L., Ashley, S., 1998. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol, 9 (3), 269-273.
  • Hickish, T.F., Smith, I.E., Nicolson, M.C., Ashley, S., Priest, K., Spencer, L., Norman, A., Middleton, G., O'Brien, M.E.R., 1998. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. British Journal of Cancer, 77 (11), 1966-1970.
  • Hickish, T.F., Smith, I.E., O'Brien, M.E.R., Ashley, S., Middleton, G., 1998. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. British Journal of Cancer, 78 (1), 28-33.
  • Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P., Walker, M., 1998. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol, 42 (1), 71-76.
  • Iveson, T., Eggleton, S.P.H., Hickish, T., Cunningham, D., Maughan, T., Harper, P., 1998. Irinotecan (CPT-11) in 5-FU pretreated advanced colorectal cancer: Results in 174 expanded access patients. ANNALS OF ONCOLOGY, 9, 36-37.
  • Mattia, E., Chichiarelli, S., Hickish, T., Gaeta, A., Mancini, C., Cunningham, D., van Renswoude, J., 1997. Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1. Oncogene, 15 (4), 489-493.
  • Webb, A., Cunningham, D., Scarffe, J.H., Harper, P., Norman, A., Joffe, J.K., Hughes, M., Mansi, J., Findlay, M., Hill, A., Oates, J., Nicolson, M., Hickish, T., O'Brien, M., Iveson, T., Watson, M., Underhill, C., Wardley, A., Meehan, M., 1997. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15 (1), 261-267.
  • Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M., Smith, I.E., 1997. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer, 76 (12), 1636-1639.
  • Hickish, T.F., Smith, I.E., Ashley, S., Middleton, G., 1996. Chemotherapy for elderly patients with lung cancer. Pneumologie, 50 (7).
  • O'Brien, M.E., Milan, S., Cunningham, D., Jones, A.L., Nicolson, M., Selby, P., Hickish, T., Hill, M., Gore, M.E., Viner, C., 1996. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. Br J Cancer, 73 (10), 1272-1277.
  • Powles, R., Raje, N., Horton, C., Mehta, J., Singhal, S., Hickish, T., Viner, C., Milan, S., Treleaven, J., Cunningham, D., 1996. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma, 21 (5-6), 421-427.
  • Findlay, M., Young, H., Cunningham, D., Iveson, A., Cronin, B., Hickish, T., Pratt, B., Husband, J., Flower, M., Ott, R., 1996. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol, 14 (3), 700-708.
  • Modjtahedi, H., Hickish, T., Nicolson, M., Moore, J., Styles, J., Eccles, S., Jackson, E., Salter, J., Sloane, J., Spencer, L., Priest, K., Smith, I., Dean, C., Gore, M., 1996. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer, 73 (2), 228-235.
  • Powles, T.J., Hickish, T., Kanis, J.A., Tidy, A., Ashley, S., 1996. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 14 (1), 78-84.
  • Nicolson, M., Webb, A., Cunningham, D., Norman, A., O'Brien, M., Hill, A., Hickish, T., 1995. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol, 6 (8), 801-804.
  • Powles, T.J., Hickish, T., 1995. Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst, 87 (18), 1343-1345.
  • Hill, M., Norman, A., Cunningham, D., Findlay, M., Watson, M., Nicolson, V., Webb, A., Middleton, G., Ahmed, F., Hickish, T., 1995. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol, 13 (9), 2317-2323.
  • Hickish, T.F., Smith, I.E., Ashley, S., Middleton, G., 1995. Chemotherapy for elderly patients with lung cancer. Lancet, 346 (8974), 580.
  • Powles, T.J., Hickish, T., 1995. Breast cancer response to hormone replacement therapy withdrawal. Lancet, 345 (8962), 1442.
  • Eisen, T., Hickish, T., Smith, I.E., Sloane, J., Eccles, S., 1995. Small-cell lung cancer. Report of a Meeting of POhysicians and Scientists at the Royal Marsden Hospital, Sutto, UK. Lancet, 345 (8960), 1285-1289.
  • Hickish, T.F., Smith, I.E., Mlddleton, G., Nicolson, M., 1995. Patient preference for extended palliative chemotherapy for non-small cell lung cancer. Lancet, 345 (8953), 857-858.
  • Hill, M., Milan, S., Cunningham, D., Mansi, J., Smith, I., Catovsky, D., Gore, M., Zulian, G., Selby, P., Horwich, A., O'Brien, M., Nicolson, M., Hickish, T., 1995. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. Journal of Clinical Oncology, 13 (2), 387-395.
  • Hill, M., Norman, A., Cunningham, D., Findlay, M., Nicolson, V., Hill, A., Iveson, A., Evans, C., Joffe, J., Nicolson, M., Hickish, T., 1995. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. Journal of Clinical Oncology, 13 (6), 1297-1302.
  • Powles, T.J., Hickish, T.F., Makris, A., Ashley, S.E., O'Brien, M.E.R., Tidy, V.A., Casey, S., Nash, A.G., Sacks, N., Cosgrove, D., MacVicar, D., Fernando, I., Ford, H.T., 1995. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology, 13 (3), 547-552.
  • Ellis, P.A., Norman, A., Hill, A., O'Brien, M.E.R., Nicolson, M., Hickish, T., Cunningham, D., 1995. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. European Journal of Cancer, 31 (10), 1594-1598.
  • McMaster, T.J., Hickish, T., Min, T., Cunningham, D., Miles, M.J., 1994. Application of scanning force microscopy to chromosome analysis. Cancer Genet Cytogenet, 76 (2), 93-95.
  • Findlay, M., Cunningham, D., Norman, A., Mansi, J., Nicolson, M., Hickish, T., Nicolson, V., Nash, A., Sacks, N., Ford, H., 1994. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol, 5 (7), 609-616.
  • Hickish, T.F., Cunningham, D., 1994. Should induction chemotherapy be considered for all patients with gastric cancer? European Journal of Surgical Oncology, 20 (2), 185-186.
  • Hickish, T., Robertson, D., Clarke, P., Hill, M., di Stefano, F., Clarke, C., Cunningham, D., 1994. Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2. Cancer Res, 54 (10), 2808-2811.
  • Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C., Malpas, J., 1994. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol, 12 (4), 759-763.
  • Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S., Selby, P.J., 1994. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol, 12 (4), 764-768.
  • McCready, V.R., Hickish, T.F., 1994. Somatostatin imaging function. Lancet, 343 (8898), 617.
  • O'Brien, M.E., Matutes, E., Cunningham, D., Hill, M., Emmett, E., Ellis, P.A., Milan, S., Hickish, T., Mercieca, J., Catovsky, D., 1994. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma, 14 Suppl 2, 17-23.
  • Hill, M., Cunningham, D., MacVicar, D., Roldan, A., Husband, J., McCready, R., Mansi, J., Milan, S., Hickish, T., 1993. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol, 11 (11), 2273-2278.
  • Hickish, T., Cunningham, D., Colston, K., Millar, B.C., Sandle, J., Mackay, A.G., Soukop, M., Sloane, J., 1993. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer, 68 (4), 668-672.
  • Hickish, T., Roldan, A., Cunningham, D., Mansi, J., Ashley, S., Nicolson, V., Gore, M.E., Catovsky, D., Smith, I.E., 1993. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer, 68 (3), 599-604.
  • Scott-Mackie, P., Hickish, T., Mortimer, P., Sloane, J., Cunningham, D., 1993. Calcipotriol and regression in T-cell lymphoma of skin. Lancet, 342 (8864), 172.
  • Powles, T.J., Hickish, T., Casey, S., O'Brien, M., 1993. Hormone replacement after breast cancer. Lancet, 342 (8862), 60-61.
  • HICKISH, T., 1993. 2'-Chlorodeoxyadenosine : evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer, 67, 139-143.
  • Hickish, T.F., Purvies, H., Mansi, J., Soukop, M., Cunningham, D., 1991. Molecular monitoring of low grade non-hodgkin’s lymphoma by gene amplification. British Journal of Cancer, 64 (6), 1161-1163.
  • Hickish, T., Cunningham, D., 1990. Gastrointestinal non-Hodgkin's lymphoma. Baillieres Clin Gastroenterol, 4 (1), 191-200.
  • Hickish, T., Colston, K.W., Bland, J.M., Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clin Sci (Lond), 77 (2), 171-176.
  • Hickish, T., Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 2 (8656).
  • HICKISH, T., CUNNINGHAM, D., 1989. DETECTING T(14-18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. LANCET, 2 (8656), 218-219.
  • Hickish, T., Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 1 (8647).
  • HICKISH, T., CUNNINGHAM, D., 1989. DETECTING T(14-18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. LANCET, 1 (8647), 1131.
  • Cunningham, D., Hickish, T., Rosin, R.D., Sauven, P., Baron, J.H., Farrell, P.J., Isaacson, P., 1989. Polymerase chain reaction for detection of dissemination in gastric lymphoma. Lancet, 1 (8640), 695-697.
  • CUNNINGHAM, D., HICKISH, T., ROSIN, R.D., SAUVEN, P., BARON, J.H., FARRELL, P.J., ISAACSON, P., 1989. POLYMERASE CHAIN-REACTION FOR DETECTION OF DISSEMINATION IN GASTRIC LYMPHOMA. LANCET, 1 (8640), 695-697.
  • Hickish, T., Colston, K.W., Bland, J.M., Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clinical Science, 77 (2).
  • Hickish, T., Cunningham, D., Haydock, A., Coombes, R.C., 1989. Experience with intermediate-dose (110-120 mg/m2) epirubicin. Cancer Chemother Pharmacol, 24 (1), 61-64.
  • Isles, S.R., Hickish, T., Cunningham, D., 1988. Chemotherapy related pulmonary embolus recognized. BMJ, 297 (6652), 854.
  • Smedley, F., Hickish, T., Taube, M., Yale, C., Leach, R., Wastell, C., 1988. Perforated duodenal ulcer and cigarette smoking. J R Soc Med, 81 (2), 92-94.
  • Smedley, F.H., Hickish, T., 1986. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut, 27 (1), 114.

Chapters

Conferences

  • Jones, R., Casbard, A., Carucci, M., Smith, J., Ingarfield, K., Gee, J.M.W., Hudson, Z., Alchami, F., Hayward, L., Hickish, T., Hwang, D., McAdam, K., Spensley, S., Waters, S., Wheatley, D., Beresford, M., 2020. Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial. ANNALS OF ONCOLOGY, 31, S1151.
  • Cidon, E.U., Alonso, P., Hickish, T., Goulbourne, S., Tyler, A., 2020. Special mouthwash and chronology of oral mucositis in previous cycle to prevent future episodes. ANNALS OF ONCOLOGY, 31, S128.
  • Thomas, D., Maxwell, W., Archer, C., Rigg, A., Hickish, T., Dent, J., Pettit, L., Dillon, M., Goldsmith, C., Verrill, M., Barthelmes, L., Khawaja, S., Sharaiha, Y., Davies, M., Arikat, F., Khan, S., Munir, A., Huws, A., Holt, S.D., 2020. Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results. CANCER RESEARCH, 80 (4).
  • Una Cidon, E., Alonso, P., Hickish, T., Tyler, A., Goulbourne, S., 2019. Preventing oral mucositis by using its chronology in prior cycle and a special mouthwash. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv66-iv67.
  • Pogue-Geile, K.L., Andre, T., Song, N., Lipchik, C., Wang, Y., Kim, R.S., Feng, H., Gavin, P., Van Laethem, J.-L., Srinivasan, A., Hickish, T., Jacobs, S.A., Tabernero, J., Lucas, P.C., De Gramont, A., Wolmark, N., Flejou, J.-F., Paik, S., 2019. Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer). JOURNAL OF CLINICAL ONCOLOGY, 37 (15).
  • Eccles, B.K., Harle, A.S., Pullinger, S., Holling, C., Ingram, A., Stark, S., Bunce, M., Melville, G., Gibbins, J., Calcutt, N., Hickish, T., Flubacher, M., Marinaki, T., 2018. Prospective DPYD testing in colorectal cancer patients in a realworld UK population. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii187.
  • Auclin, E., Andre, T., Taieb, J., Banzi, M., van Laethem, J.L., Tabernero, J., Hickish, T., de Gramont, A., Vernerey, D., 2018. Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): Post hoc analysis of the MOSAIC trial. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii154.
  • Auclin, E., Taieb, J., Lepage, C., Aparicio, T., Faroux, R., Mini, E., Folprecht, G., Salazar, R., Banzi, M., Louvet, C., Van Laethem, J.-L., Tabernero, J., Hickish, T., De Gramont, A., Andre, T., Vernerey, D., 2018. Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies. JOURNAL OF CLINICAL ONCOLOGY, 36 (15).
  • Jeffery, J., Murphy, J.L., Hewitt-Taylor, J., Hickish, T., 2018. Longitudinal study of energy and macronutrient intake during the first year following treatment for early stage breast cancer. PROCEEDINGS OF THE NUTRITION SOCIETY, 77 (OCE1), E10.
  • Bridgewater, J., Pugh, S., Whitehead, A., Stanton, L., Eminton, Z., Mellor, J., Allen, A., Finch-Jones, M., Falk, S., Iveson, T., Rees, M., Valle, J.W., Hornbuckle, J., Hickish, T., Cunningham, D., Maughan, T., Garden, J., Griffiths, G., Primrose, J., 2017. Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial. ANNALS OF ONCOLOGY, 28.
  • Neoptolemos, J.P., Palmer, D., Greenhalf, W., Ghaneh, P., Jackson, R., Evans, A., Shaw, V., Wadsley, J., Valle, J.W., Wasan, H., Falk, S., Cunningham, D., Coxon, F.Y., Ross, P.J., Wadd, N., Hickish, T., Costello, E., Campbell, F., Rawcliffe, C., Middleton, G.W., 2017. Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 35.
  • Wyrwicz, L., Saunders, M.P., Andre, T., Sarosiek, T., Nemecek, R., Rogowski, W., Leniewski-Kmak, K., Fisher, G.A., Stecher, M., Mohanty, P., Simard, J., Hickish, T., 2017. MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (P1026). JOURNAL OF CLINICAL ONCOLOGY, 35.
  • Hickish, T., Mohanty, P., Michael, S., Shivaswamy, S., Sunley, K., Varshney, A., Martin, R., Simard, J., 2017. Modulation of platelet levels by an anti-IL-1α antibody (MABp1) in advanced colorectal cancer patients. EUROPEAN JOURNAL OF CANCER, 72, S70.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S., Cortes, J., 2017. Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA). CANCER RESEARCH, 77.
  • Vaughan, N., Dubey, V.N., Hickish, T., Cole, J., 2017. A smart device to substitute the neurothesiometer. Proceedings of the ASME Design Engineering Technical Conference, 3.
  • Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Nemecek, R., Kocsis, J., Stecher, M., de Gramont, A., 2016. A pivotal phase 3 trial of MABp1 in advanced colorectal cancer. ANNALS OF ONCOLOGY, 27, 128.
  • Earl, H.M., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D.A., Provenzano, E., Thomas, J., Hayward, L., 2016. Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial. JOURNAL OF CLINICAL ONCOLOGY, 34 (15).
  • Hickish, T., Purandare, L., 2015. A pilot study to assess the safety and feasibility of pre-chemotherapy assessment using telemedicine. In: Phi Mu Chapter Biannual Conference 19/06/2015 Leeds.
  • Cidon, E.U., Alonso, P., Needham, S., Hickish, T., 2015. First cycle dose calculation in obese patients with colorectal cancers. ANNALS OF ONCOLOGY, 26.
  • Earl, H.M., Hiller, L., Dunn, J.A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D., Hayward, L., 2015. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer. CANCER RESEARCH, 75.
  • Abbey, G., Thompson, S.B.N., Hickish, T., Heathcote, D., 2015. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. Psycho Oncology, 24 (4), 371-381.
  • Hickish, Earl, H., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D., Hayward, L., 2014. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 02/11/2014 Liverpool.
  • Petricoin, E.F., Wulfkuhle, J., Hickish, T., El-Hariry, I., Reichert, V., Vukovic, V.M., Cameron, D.A., Awada, A., Spector, N., 2014. Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negat. CANCER RESEARCH, 74 (19).
  • Bridgewater, J., Pugh, S., Moutasim, K., Thomas, G., Thiébaut, R., Liebaert, F., Falk, S., Finch-Jones, M., Valle, J., O’Reilly, D., Siriwardena, A., Hornbuckle, J., Rees, M., Iveson, T., Hickish, T., Bowers, M., Garden, J., Cunningham, D., Maughan, T., Primrose, J., 2014. Analysis of progression free survival in the New EPOC study in an all RAS wild-type population. In: ESMO 2014 Congress 26/09/2014 Madrid, Spain.
  • Abbey, G., Thompson, S.B.N., Hlickish, T., Heathcota, D., 2014. A meta-analysis of prevalence rates and moderating factors for cancer related post-traumatic stress disorder. JOURNAL OF CLINICAL ONCOLOGY, 32 (15).
  • Cameron, D.A., Spector, N., Cortes, J., Mano, M.S., Canon, J.-L.R., Hickish, T., Vandat, L.T., Kim, S.-B., Gomez, H.L., El-Hariry, I., Vukovic, V.M., Sheldon, E.H., Perez, E.A., Awada, A., 2014. Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 32 (15).
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T., Mayers, A., 2014. Prospective memory and cognitive impairment in breast cancer patients. In: 4th International Conference on Prospective Memory 26/05/2014 Suor Orsola Benincasa University, Naples.
  • Cameron, D., Spector, N., Gomez, H., Hickish, T., Vandat, L., Kim, S.B., Sheldon, E., El-Hariry, I., Perez, E., Awada, A., 2014. Targeting HSP90 in breast cancer: ENCHANT-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer (TNBC). EUROPEAN JOURNAL OF CANCER, 50, S98.
  • Schroeder, J.W., Dubey, V., Hickish, T., Cole, T.. Intelligent Agent Based Software Architecture of a Wearable Electrotactile Feedback System for Balance Improvement. In: 2014 International Academic Conference on Engineering, Internet and Technology 12/12/2014 Prague. Proceedings of IAC-ElaT 2014.
  • Una Cidon, E., Hickish, T., Alonso, P.. Cardiac Toxicity with Fluoropyrimidines in Colorectal Cancer. In: ESMO World GI 2014 25/06/2014 Barcelona, Spain. Annals of Oncology, 2 (25).
  • Una Cidon, E., Hickish, T., Alonso, P., 2014. Cetuximab as Monotherapy in Elderly Patients with Metastatic Colorectal Cancer. In: ESMO World GI 2014 25/06/2014 Barcelona, Spain. Annals of Oncology, 2 (25).
  • André, T., de Gramont, A., Chibaudel, B., Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J.L., Banzi, M., Maartense, E., Shani, A., Carlsson, G., Scheithauer, W., Papamichael, D., Möhler, M., Landolfi, S., Demetter, P., Dumont, S., Fléjou, J.F., de Gramont, A.. MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators. In: ESMO 2014 26/09/2014 Madrid, Spain. Annals of Oncology, 4 (25).
  • Schroeder, J.W., Dubey, V., Hickish, T., Cole, T.. Intelligent Agent Based Software Architecture of a Wearable Electrotactile Feedback System for Balance Improvement. In: International Academic Conference on Engineering, Internet and Technology 12/12/2014 Prague. Proceedings of IAC-ElaT 2014.
  • Earl, H., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D., Hayward, L.. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 02/11/2014 Liverpool.
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T., Mayers, A., 2013. Cognitive decline as a result of impaired sleep and glucose levels during chemotherapy treatment in breast cancer patients. In: American Society of Clinical Oncology 31/05/2013 McCormick Place, Chicago, USA.
  • Flejou, J.-F., Andre, T., Chibaudel, B., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J.-L., Banzi, M., Maartense, E., Shani, A., Carlsson, G., Scheithauer, W., Papamichael, D., Moehler, M., Landolfi, S., Demetter, P., Duval, A., Lee, M., Colote, S., De Gramont, A., 2013. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. JOURNAL OF CLINICAL ONCOLOGY, 31 (15).
  • Primrose, J.N., Falk, S., Finch-Jones, M., Valle, J.W., Sherlock, D., Hornbuckle, J., Gardner-Thorpe, J., Smith, D., Imber, C., Hickish, T., Davidson, B., Cunningham, D., Poston, G.J., Maughan, T., Rees, M., Stanton, L., Little, L., Bowers, M., Wood, W., Bridgewater, J.A., 2013. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. JOURNAL OF CLINICAL ONCOLOGY, 31 (15).
  • Hickish, T., Mehta, A., Jain, M., Huang, C.-S., Kovalenko, N., Udovitsa, D., Pemberton, K., Uttenreuther-Fischer, M., Tseng, L.-M., 2012. LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib. CANCER RESEARCH, 72.
  • Schroeder, J.W., Dubey, V.N., Hickish, T., Cole, J., Mecheraoui, C., Swain, I.. Applications of electrical stimulation and electrotactile feedback in human spaceflight. In: 63rd International Astronautical Congress 01/10/2012 Naples, Italy.
  • Moyers-Ruiz, L., Hickish, T., Thompson, S., 2012. Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment. JOURNAL OF CLINICAL ONCOLOGY, 30 (15).
  • Hickish, T., Tseng, L.-M., Mehta, A.O., Tsang, J., Kovalenko, N., Udovitsa, D., Pelling, K., Uttenreuther-Fischer, M.M., Huang, C.-S., 2012. LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). JOURNAL OF CLINICAL ONCOLOGY, 30 (15).
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F., Cole, J., 2012. Wearable Electrocutaneous Feed-back System: A Smart Device to Compensate for Sensation Loss. In: Design of Medical Devices 10/04/2012 Minneapolis, Minnesota, USA.
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F., Cole, J., 2012. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. In: Design of Medical Devices 10/04/2012 Minneapolis, Minnesota, USA.
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T., 2012. Prospective and working memory decline in breast cancer patients during chemotherapy. In: International Cognition & Cancer Task Force 15/03/2012 Espace Saint-Martin, Paris, France.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Hegg, R., Tausch, C., Seo, J.H., Tsai, Y.F., McNally, V., Cortes, J., 2012. Pertuzumab and Trastuzumab in Combination with an Anthracycline-containing or an Anthracycline-free Standard Chemotherapy in the Neoadjuvant Treatment of HER2-positive Breast Cancer (TRYPHAENA). EUROPEAN JOURNAL OF CANCER, 48, S96.
  • Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T., 2012. Longitudinal study of prospective and working memory decline in breast cancer patients undergoing chemotherapy. In: British Psychosocial Oncology Society Annual Conference 19/01/2012 Metropole Hotel, Leeds.
  • Schroeder, J., Dubey, V., Hickish, T., Cole, J.. Creation of Artificial Sensation by Tactile Sensing and Intelligent Stimulation of Sensory Nerves. In: DEC Researchers Poster Conference. 12/2012 Bournemouth.
  • Schroeder, J., Dubey, V., Hickish, T., Cole, J.. Multisensory Intelligent Feedback System for Sensory Substitution using Electrical Stimulation. In: DEC Researchers Poster Conference 2012 Bournemouth.
  • Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J.-H., Tsai, Y.-F., Ackrill, A., Ross, G., Cortes, J., 2011. Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA). CANCER RESEARCH, 71.
  • Shipway, R., Jones, I., Holloway, I., 2011. Healthy Options? Putting your (Running) body on the line. International Sociology of Sport Association.
  • Seymour, M.T., Brown, S.R., Richman, S., Middleton, G.W., Maughan, T., Olivier, C., Gwyther, S.J., Wadsley, J., Chau, I., Hickish, T., Dawson, L.K., Falk, S., O'Callaghan, A., Benstead, K., Wadd, N., Oliver, A., Chambers, P., Marshall, H., Napp, V., Quirke, P., 2011. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). JOURNAL OF CLINICAL ONCOLOGY, 29 (15).
  • Schroeder, J.W., Dubey, V.N., Hickish, T.F., Cole, J., 2011. Electrocutaneous feedback system to improve the estimation of pressure applied to the foot. In: International Conference on Biomedical Electronics and Devices (BIODEVICES 2011) 26/01/2011 Rome, Italy.
  • Schroeder, J., Dubey, V., Hickish, T., Cole, J.. Electrocutaneous Feedback System for Patients with Loss of Sensation in their Feet. In: Salisbury FES User Day 2011 Salisbury.
  • Schroeder, J.W., Dubey, V.N., Hickish, T., Cole, J.. Electrocutaneous Feedback System to Improve the Estimation of Pressure Applied to the Foot. BIODEVICES SciTePress.
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H., Winer, E., 2009. Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. CANCER RESEARCH, 69 (24), 785S.
  • Wong, R., Saffery, C., Barbachano, Y., Chau, I., Valle, J., Hickish, T., Mudan, S., Khan, A., Chua, Y.J., Cunningham, D., 2009. BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. EJC SUPPLEMENTS, 7 (2), 344-345.
  • Purandare, L., Baker, R., Hickish, T., 2009. Can oncology nurses and other allied health professionals learn to treat post traumatic stress disorder in cancer survivors. EJC SUPPLEMENTS, 7 (2), 196.
  • Purandare, L., Hickish, T., Astras, G., Penfold, S., Thomas, F., Kerr, D., 2009. Impaired glucose tolerance in non-diabetic women during adjuvant chemotherapy for breast cancer. EJC SUPPLEMENTS, 7 (2), 309.
  • Earl, H.M., Vallier, A., Hiller, L., Fenwick, N., Iddawela, M., Hughes-Davies, L., Provenzano, E., McAdam, K., Hickish, T., Caldas, C., 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). JOURNAL OF CLINICAL ONCOLOGY, 27 (15).
  • Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H., Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. JOURNAL OF CLINICAL ONCOLOGY, 27 (15).
  • de Gramont, A., Buyse, M., Abrahantes, J.C., Burzykowski, T., Quinaux, E., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Mineur, L., Carola, E., Etienne, P.-L., Rivera, F., Chirivella, I., Perez-Staub, N., Louvet, C., André, T., Tabah-Fisch, I., Tournigand, C., 2007. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. United States. J Clin Oncol, 25 (22), 3224-3229.
  • Chau, I., Starling, N., Cunningham, D., Oates, J., Iveson, T., Nicolson, M., Hawkins, R., Hickish, T., Seymour, M., Norman, A., 2007. Does histology influence outcome in advanced oesophagogastric (OG) cancer? Individual patient data from 1,680 patients on three randomised controlled trials (RCT). JOURNAL OF CLINICAL ONCOLOGY, 25 (18).
  • de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Lorenzato, C., Andre, T., 2007. FOLFOX4 in adjuvant treatment of colon cancer: Survival results from the mosaic trial. ANNALS OF ONCOLOGY, 18, VII23.
  • Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G., Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). JOURNAL OF CLINICAL ONCOLOGY, 24 (18), 147S.
  • de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Marceau-Suissa, J., Lorenzato, C., André, T., 2005. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer:: Efficacy results with a median follow-up of 4 years. JOURNAL OF CLINICAL ONCOLOGY, 23 (16), 246S.
  • Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T., De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 274S.
  • Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J., Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 276S.
  • Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M., Hickish, T., 2004. Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 318S.
  • Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FUV leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 250S.
  • Harper-Wynne, C., Sumpter, K., Cunningham, D., Norman, A., Oates, J., Durrant, C., Iveson, T., Nicholson, M., Hickish, T., Hill, M., 2003. Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation. BRITISH JOURNAL OF CANCER, 88, S22.
  • Powles, R., Cunnigham, D., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hickish, T., Nicolson, M., Johnson, P., Treleaven, J., Raymond, J., Gore, M., 1998. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: Results 51/2 years after the accrual of the last patient. BONE MARROW TRANSPLANTATION, 21, S209.
  • Powles, R., Cunningham, D., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hickish, T., Nicolson, M., Johnson, P., Treleaven, J., Raymond, J., Gore, M., 1997. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: Results 5 1/2 years after accrual of the last patient. BLOOD, 90 (10), 1588.
  • Raje, N., Powles, R., Hickish, T., Horton, C.A.P., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J., Cunningham, D., 1995. Outcome of relapsed/resistant multiple myeloma: The Royal Marsden experience. BLOOD, 86 (10), 3352.
  • Raje, N., Powles, R., Hickish, T., Milan, S., Horton, C., Mehta, J., Singhal, S., Treleaven, J., Cunningham, D., 1995. Beta 2 microglobulin levels in patients of myeloma following high dose treatment and interferon maintenance. BLOOD, 86 (10), 3351.
  • Powles, R., Raje, N., Milan, S., Hickish, T., Mehta, J., Singhal, B., Viner, C., Treleaven, J., Cunningham, D., 1995. Prognostic factors in multiple myeloma. BLOOD, 86 (10), 733.
  • Powles, R., Raje, N., Milan, S., Mehta, J., Singhal, S., Hickish, T., Viner, C., Treleaven, J., Cunningham, D., 1995. Impact of induction chemotherapy followed by high dose treatment in previously untreated myeloma: A since centre experience. BLOOD, 86 (10), 732.
  • Raje, N., Powles, R., Milan, S., Hickish, T., Mehta, J., Singhal, S., Viner, C., Treleaven, J., Cunningham, D., 1995. Induction treatment with VAMP/C-VAMP infusional chemotherapy in previously untreated myeloma. BLOOD, 86 (10), 731.
  • Raje, N., Powles, R., Horton, C., Middleton, G., Hickish, T., Mehta, J., Singhal, S., Morton, C., Porter, H., Viner, C., Treleaven, J., 1995. Peripheral blood transplants followed by maintenance interferon in myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 814.
  • Singhal, S., Powles, R., Cunningham, D., Hickish, T., Middleton, G., Raje, N., Viner, C., Mehta, J., 1995. Second autografts for relapsed myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 801.
  • Raje, N., Powles, R., Hickish, T., Gore, M., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J., Cunningham, D., 1995. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 799.
  • Powles, R., Raje, N., Hickish, T., Middleton, G., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J., Cunningham, D., 1995. Single centre results of therapy including autografts in previously untreated myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 797.
  • Middleton, G.W., Mehta, J., Porter, H., Miller, B.C., Bell, J.A., Raje, N., Hickish, T., Shepherd, V., Powles, R.L., 1995. Comparison of two stem cell mobilization and harvesting regimens for peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM). EUROPEAN JOURNAL OF CANCER, 31A, 246.
  • CUNNINGHAM, D., HILL, M.E., MILAN, S., MANSI, J.L., SMITH, I.E., CATOVSKY, D., GORE, M., OBRIEN, M.E.R., NICOLSON, M., HICKISH, T., 1994. VEEP CHEMOTHERAPY FOR ADULT HODGKINS-DISEASE - ASSESSMENT OF EFFICACY AND GONADAL AND CARDIAC TOXICITY. BLOOD, 84 (10), A162.
  • CUNNINGHAM, D., OBRIEN, M.E.R., HILL, M., MILAN, S., NICOLSON, M., JONES, A.L., VINER, C., HICKISH, T., 1994. HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANT IN HODGKINS-DISEASE - THE ROYAL-MARSDEN-HOSPITAL EXPERIENCE. BLOOD, 84 (10), A162.
  • CLARKE, P., HICKISH, T., ROBERTSON, D., HILL, M., DISTEFANO, F., CONNINGHAM, D., 1994. IN-VIVO EXPRESSION AND LOCALIZATION OF BHRF-1, AN EPSTEIN-BARR-VIRUS (EBV) ENCODED BCL-2 HOMOLOG. JOURNAL OF CELLULAR BIOCHEMISTRY, 230.
  • ADSHEAD, F.J., HICKISH, T., PURVIES, H., CUNNINGHAM, D., SMITH, I.E., MILLAR, J.L., 1991. INTERLEUKIN-3 GENE-EXPRESSION IN CYCLOPRIMED BONE-MARROW. EXPERIMENTAL HEMATOLOGY, 19 (6), 523.
  • HICKISH, T., SOUKOP, M., MILLAR, B.C., MCELWAIN, T.J., CUNNINGHAM, D., 1990. GROWTH MODULATION OF 2 LYMPHOMA CELL-LINES BY A NOVEL CALCITRIOL ANALOG MC903. BRITISH JOURNAL OF CANCER, 62 (3), 493-494.
  • HICKISH, T., SOUKOP, M., MCELWAIN, T.J., CUNNINGHAM, D., 1990. DISEASE ASSESSMENT WITH THE POLYMERASE CHAIN-REACTION (PCR) IN FOLLICULAR SMALL CLEAVED CELL LYMPHOMA. BRITISH JOURNAL OF CANCER, 62 (3), 485.
  • CUNNINGHAM, D., HICKISH, T., ROSIN, D., SAUVEN, P., BARON, H., FARRELL, P.J., ISAACSON, P., 1989. PCR USED TO DETECT DISSEMINATION IN GASTRIC LYMPHOMA - IMPLICATIONS FOR TREATMENT. BRITISH JOURNAL OF CANCER, 60 (3), 447.
  • HICKISH, T., JOHNSON, M., COLSTON, K., MAXWELL, J.D., 1986. MUSCLE STRENGTH AND VITAMIN-D STATUS IN MALE-ALCOHOLICS. CLINICAL SCIENCE, 71, P86.

Patents

PhD Students

  • Ejike Thankgod Ezeh. Web-Based Information Tool for People withAdvanced Cancer IRAS no:252843
  • Mohammad Naiseh. Explainable AI in Healthcare

External Responsibilities

  • Dorset Cancer Centre c/o Royal Bournemouth and Poole Hospitals, Consultant Medical Oncologist
  • iQHealth Tech, Medical Director

Memberships

  • Royal College of Physicians, Fellow,
The data on this page was last updated at 05:00 on February 18, 2026.